Select a medication above to begin.
Widaplik
telmisartan/ amlodipine/ indapamide
Black Box Warnings .
Fetal Toxicity
fetal/neonatal morbidity/mortality may occur when drugs that act directly on the renin-angiotensin system are used in pregnancy; D/C drug ASAP once pregnancy detected
Adult Dosing .
Dosage forms: TAB: 10 mg/1.25 mg/0.625 mg, 20 mg/2.5 mg/1.25 mg, 40 mg/5 mg/2.5 mg
HTN
- [1 tab PO qd]
- Start: 10 mg/1.25 mg/0.625 mg or 20 mg/2.5 mg/1.25 mg PO qd, may incr. dose after 2wk; Max: 40 mg/5 mg/2.5 mg/day; Info: do not cut/crush/chew tab
renal dosing
- [see below]
- renal impairment: not defined, caution advised; anuria: contraindicated
- HD/PD: not defined
hepatic dosing
- [adjust dose amount]
- hepatic impairment: start 10 mg/1.25 mg/0.625 mg qd, titrate slowly
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
-
com.epocrates.rxweb.beans.StringCollection@36805074
- hypersensitivity to drug or ingredient
- pregnancy
- anuria
- avoid: sun exposure
- avoid: UV light exposure, artificial
- caution: hypersensitivity to sulfonamides
- caution: elderly patients
- caution: renal artery stenosis
- caution: renal impairment
- caution: hepatic impairment
- caution: hepatic disease, progressive
- caution: electrolyte abnormalities
- caution: volume depletion
- caution: hyponatremia
- caution: hyperkalemia risk
- caution: CHF
- caution: CAD, severe obstructive
- caution: aortic stenosis, severe
- caution: arrhythmia
- caution: post-sympathectomy
- caution: seizure disorder
- caution: diabetes mellitus
- caution: SLE
- caution: gout history
- caution: pancreatitis history
- caution: HTN, gestational
Drug Interactions .
Overview
amlodipine
CCB, dihydropyridine
- CYP3A4 substrate
- CYP3A4 inhibitor, weak
- alters gallbladder contraction/motility
- angioedema
- antihypertensive agent
- binds to cation exchange resin/polymer
- levamlodipine is the active isomer of racemic amlodipine; similar interactions anticipated
indapamide
thiazide diuretic
- antihypertensive agent
- binds to anion exchange resin/polymer
- decreases renal perfusion/fxn
- diuretic
- hypercalcemia
- hyperglycemic effects
- hyperuricemic effects
- hypokalemia
- hypomagnesemia
- hyponatremia
- photosensitivity
- urine alkalinizer
telmisartan
ARB
- P-gp inhibitor, weak
- BCRP inhibitor
- UGT1A9 inducer
- angiotensin II Type 1 antagonist
- antihypertensive agent
- binds to cation exchange resin/polymer
- decreases renal perfusion/fxn
- hyperkalemia
- hypoglycemic effects
Contraindicated
- aliskiren
- cisapride
- colchicine
- eliglustat
- isocarboxazid
- methenamine
- sparsentan
Contraindicated
telmisartan + aliskiren
contraindicated in diabetic patients; avoid combo in pts w/ CrCl <60; for all other pts, use alternative or monitor BP, potassium, renal fxn: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Contraindicated
amlodipine + cisapride
contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
Contraindicated
telmisartan + colchicine
CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, consider decr. colchicine dose during and x14 days after telmisartan use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (P-gp-mediated transport inhibited)
Avoid/Use Alternative
amlodipine + colchicine
CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT or FMF: use alternative or consider decr. colchicine dose during and x14 days after amlodipine use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited)
Contraindicated
amlodipine + eliglustat
CYP2D6 EM: contraindicated if Child-Pugh Class A and if also combined w/ moderate or strong CYP2D6 inhibitor; if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 IM: if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
Contraindicated
amlodipine + isocarboxazid
contraindicated: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + isocarboxazid
contraindicated: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + isocarboxazid
contraindicated: combo may incr. risk of hypotension, including orthostasis (additive effects)
Contraindicated
indapamide + methenamine
contraindicated: combo may decr. methenamine efficacy; may incr. risk of crystalluria (decreased conversion of methenamine to formaldehyde in alkaline urine; sulfonamides may precipitate with formaldehyde)
Contraindicated
telmisartan + sparsentan
contraindicated: combo may incr. risk of hyperkalemia, nephrotoxicity, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
amlodipine + sparsentan
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + sparsentan
monitor BP, renal fxn: combo may incr. risk of nephrotoxicity, hypotension, including orthostasis, syncope (additive effects)
Avoid/Use Alternative
- acoramidis
- aldesleukin
- alpelisib
- alprazolam
- amikacin
- amiloride
- aminolevulinic acid topical
- angiotensin II
- apixaban
- aripiprazole lauroxil
- arsenic trioxide
- azilsartan medoxomil
- benazepril
- candesartan cilexetil
- captopril
- ceritinib
- chlorothiazide
- chlorthalidone
- cladribine oral
- clofarabine
- codeine
- dabigatran
- dantrolene
- diltiazem
- enalapril
- enalaprilat
- ensartinib
- felodipine
- fosinopril
- hydrochlorothiazide
- hydrocodone
- iodixanol
- iomeprol
- iopromide
- ioversol
- irbesartan
- isradipine
- lisinopril
- lofexidine
- losartan
- mannitol
- meperidine
- methadone
- metolazone
- moexipril
- neratinib
- nicardipine
- nifedipine
- nimodipine
- nisoldipine
- olmesartan medoxomil
- oxycodone
- pazopanib
- perindopril
- pimozide
- porfimer
- potassium chloride
- potassium phosphate
- pralsetinib
- propafenone
- quinapril
- ramipril
- relugolix
- repotrectinib
- rivaroxaban
- simvastatin
- sirolimus albumin-bound
- sulfamethoxazole
- tacrolimus
- telmisartan
- topotecan
- trandolapril
- tretinoin topical
- valsartan
- venetoclax
- verapamil
Avoid/Use Alternative
telmisartan + acoramidis
avoid combo: combo may decr. acoramidis levels, efficacy (UGT possibly induced)
Avoid/Use Alternative
amlodipine + aldesleukin
avoid combo: combo may incr. risk of severe or life-threatening hypotension (additive effects)
indapamide + aldesleukin
avoid combo: combo may incr. risk of severe or life-threatening hypotension (including orthostasis), renal impairment (additive effects)
telmisartan + aldesleukin
avoid combo: combo may incr. risk of severe or life-threatening hypotension (additive effects)
Avoid/Use Alternative
telmisartan + alpelisib
use alternative: combo may incr. alpelisib levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)
Avoid/Use Alternative
amlodipine + alprazolam
use alternative or monitor respiratory rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)
Avoid/Use Alternative
indapamide + amikacin
use alternative or monitor amikacin levels, renal fxn, ototoxicity: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
telmisartan + amikacin
use alternative or monitor amikacin levels, renal fxn, ototoxicity: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Avoid/Use Alternative
telmisartan + amiloride
if hypokalemia use, monitor potassium; otherwise, avoid combo: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
indapamide + amiloride
monitor sodium, renal fxn: combo may incr. risk of renal impairment, severe hyponatremia, other adverse effects (additive effects, duplicate therapy)
Avoid/Use Alternative
indapamide + aminolevulinic acid topical
avoid combo: combo may incr. risk of photosensitivity reaction (additive effects)
Avoid/Use Alternative
telmisartan + angiotensin II
use alternative or monitor BP: combo may decr. angiotensin II efficacy (antagonistic effects)
Avoid/Use Alternative
telmisartan + apixaban
ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)
Avoid/Use Alternative
amlodipine + aripiprazole lauroxil
ARISTADA INITIO: avoid combo; ARISTADA: monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + aripiprazole lauroxil
ARISTADA INITIO: avoid combo; ARISTADA: monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + aripiprazole lauroxil
ARISTADA INITIO: avoid combo; ARISTADA: monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Avoid/Use Alternative
indapamide + arsenic trioxide
use alternative or monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)
Avoid/Use Alternative
telmisartan + azilsartan medoxomil
avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
indapamide + azilsartan medoxomil
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
telmisartan + benazepril
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + benazepril
monitor renal fxn, sodium: combo may incr. risk of renal impairment, severe hyponatremia (additive effects)
Avoid/Use Alternative
telmisartan + candesartan cilexetil
avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
indapamide + candesartan cilexetil
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
telmisartan + captopril
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + captopril
monitor renal fxn, sodium: combo may incr. risk of renal impairment, severe hyponatremia (additive effects)
Avoid/Use Alternative
amlodipine + ceritinib
use alternative or monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Avoid/Use Alternative
indapamide + chlorothiazide
avoid combo: combo may incr. risk of renal impairment, severe hyponatremia, seizures, hypokalemia, hypomagnesemia, hypercalcemia, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
telmisartan + chlorothiazide
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
indapamide + chlorthalidone
avoid combo: combo may incr. risk of renal impairment, severe hyponatremia, hypokalemia, hypomagnesemia, hypercalcemia, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
telmisartan + chlorthalidone
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
telmisartan + cladribine oral
use alternative or monitor CBC: combo may incr. cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited)
Avoid/Use Alternative
indapamide + clofarabine
avoid indapamide during 5 day clofarabine tx; monitor CBC, renal fxn, BP: combo may incr. clofarabine levels, risk of serious infection, myelosuppression, nephrotoxicity, severe hypotension (including orthostasis), other adverse effects (additive effects)
telmisartan + clofarabine
avoid telmisartan during 5 day clofarabine tx; monitor CBC, renal fxn, BP: combo may incr. clofarabine levels, risk of serious infection, myelosuppression, nephrotoxicity, severe hypotension, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + clofarabine
monitor BP: combo may incr. risk of severe hypotension (additive effects)
Avoid/Use Alternative
amlodipine + codeine
use alternative or monitor respiratory rate, BP; consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, may incr. production of active metabolite morphine; additive effects)
Monitor/Modify Tx
indapamide + codeine
monitor BP: combo may decr. indapamide efficacy; may incr. risk of severe hypotension, including orthostasis, syncope (antagonistic effects, opioids may induce antidiuretic hormone release; additive effects)
telmisartan + codeine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Avoid/Use Alternative
telmisartan + dabigatran
ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)
Avoid/Use Alternative
amlodipine + dantrolene
use alternative: combo may incr. risk of arrhythmias, cardiovascular collapse (mechanism unknown)
Avoid/Use Alternative
amlodipine + diltiazem
avoid combo: combo may incr. (lev)amlodipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited, duplicate therapy)
Avoid/Use Alternative
telmisartan + enalapril
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + enalapril
monitor renal fxn, sodium: combo may incr. risk of renal impairment, severe hyponatremia (additive effects)
Avoid/Use Alternative
telmisartan + enalaprilat
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + enalaprilat
monitor renal fxn, sodium: combo may incr. risk of renal impairment, severe hyponatremia (additive effects)
Avoid/Use Alternative
telmisartan + ensartinib
avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)
Avoid/Use Alternative
amlodipine + felodipine
avoid combo: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metabolism inhibited, additive effects; duplicate therapy)
Avoid/Use Alternative
telmisartan + fosinopril
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + fosinopril
monitor renal fxn, BP, sodium: combo may incr. risk of renal impairment, severe hyponatremia, hypotension (additive effects)
Avoid/Use Alternative
indapamide + hydrochlorothiazide
avoid combo: combo may incr. risk of renal impairment, severe hyponatremia, hypokalemia, hypercalcemia, hypomagnesemia, cardiac arrhythmias, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
telmisartan + hydrochlorothiazide
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
amlodipine + hydrocodone
use alternative or monitor respiratory rate, ECG, BP; consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
Monitor/Modify Tx
indapamide + hydrocodone
monitor BP; consider incr. indapamide dose: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + hydrocodone
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Avoid/Use Alternative
indapamide + iodixanol
avoid indapamide prior to iodixanol administration: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
telmisartan + iodixanol
monitor renal function: combo may incr. risk of nephrotoxicity (additive effects)
Avoid/Use Alternative
indapamide + iomeprol
avoid combo: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
telmisartan + iomeprol
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Avoid/Use Alternative
indapamide + iopromide
avoid combo: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
telmisartan + iopromide
monitor renal function: combo may incr. risk of nephrotoxicity (additive effects)
Avoid/Use Alternative
indapamide + ioversol
avoid indapamide prior to ioversol administration: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
telmisartan + ioversol
monitor renal function: combo may incr. risk of nephrotoxicity (additive effects)
Avoid/Use Alternative
telmisartan + irbesartan
avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
indapamide + irbesartan
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
amlodipine + isradipine
avoid combo: combo may incr. risk of hypotension, edema, other adverse effects (additive effects; duplicate therapy)
Avoid/Use Alternative
telmisartan + lisinopril
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + lisinopril
monitor renal fxn, sodium: combo may incr. risk of renal impairment, severe hyponatremia (additive effects)
Avoid/Use Alternative
amlodipine + lofexidine
use alternative or monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + lofexidine
use alternative or monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + lofexidine
use alternative or monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Avoid/Use Alternative
telmisartan + losartan
avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
indapamide + losartan
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
indapamide + mannitol
use alternative or monitor renal fxn, electrolytes, ECG: combo may incr. mannitol levels, risk of renal impairment, neurotoxicity (including life-threatening), hypokalemia, QT prolongation, cardiac arrhythmias, severe hyponatremia (including life-threatening), seizures, other adverse effects (additive effects, duplicate therapy)
Avoid/Use Alternative
amlodipine + meperidine
use alternative or monitor respiratory rate, ECG, BP: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
Monitor/Modify Tx
indapamide + meperidine
monitor BP; consider incr. indapamide dose: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + meperidine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Avoid/Use Alternative
amlodipine + methadone
use alternative or monitor respiratory rate, BP, ECG; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
Monitor/Modify Tx
indapamide + methadone
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + methadone
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Avoid/Use Alternative
indapamide + metolazone
avoid combo: combo may incr. risk of renal impairment, severe hyponatremia (including life-threatening), hypokalemia, hypercalcemia, hypomagnesemia, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
telmisartan + metolazone
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
telmisartan + moexipril
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + moexipril
monitor renal fxn, sodium: combo may incr. risk of renal impairment, severe hyponatremia (additive effects)
Avoid/Use Alternative
telmisartan + neratinib
avoid combo if also combined w/ mod-strong CYP3A4 inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (P-gp-mediated transport inhibited)
Avoid/Use Alternative
amlodipine + nicardipine
avoid combo: combo may incr. risk of hypotension, edema, other adverse effects (additive effects; duplicate therapy)
Avoid/Use Alternative
amlodipine + nifedipine
avoid combo: combo may incr. nifedipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited, additive effects; duplicate therapy)
Avoid/Use Alternative
amlodipine + nimodipine
avoid combo: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited; duplicate therapy)
Avoid/Use Alternative
amlodipine + nisoldipine
avoid combo: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited; duplicate therapy)
Avoid/Use Alternative
telmisartan + olmesartan medoxomil
avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
indapamide + olmesartan medoxomil
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
amlodipine + oxycodone
use alternative or monitor respiratory rate, BP; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
Monitor/Modify Tx
indapamide + oxycodone
monitor BP: combo may decr. indapamide efficacy; may incr. risk of severe hypotension, including orthostasis, syncope (antagonistic effects, opioids may induce antidiuretic hormone release; additive effects)
telmisartan + oxycodone
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Avoid/Use Alternative
telmisartan + pazopanib
avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. antihypertensive agent efficacy (BCRP-mediated transport inhibited; antagonistic effects)
Monitor/Modify Tx
amlodipine + pazopanib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + pazopanib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Avoid/Use Alternative
telmisartan + perindopril
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + perindopril
monitor renal fxn, sodium: combo may incr. risk of renal impairment, severe hyponatremia (additive effects)
Avoid/Use Alternative
amlodipine + pimozide
use alternative or monitor ECG: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
Avoid/Use Alternative
indapamide + porfimer
avoid combo: combo may incr. risk of photosensitivity reaction (additive effects)
Avoid/Use Alternative
telmisartan + potassium chloride
IV potassium chloride: use alternative or monitor potassium, ECG; ORAL potassium: monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)
Avoid/Use Alternative
telmisartan + potassium phosphate
use alternative or monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)
Avoid/Use Alternative
amlodipine + pralsetinib
if also combined w/ P-gp inhibitor, use alternative or monitor BP, consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd; otherwise, monitor BP, consider monitoring ECG, electrolytes: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)
telmisartan + pralsetinib
use alternative or monitor BP, consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 400 mg qd and also combined w/ strong CYP3A4 inhibitor: decr. to 200 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. antihypertensive agent efficacy (P-gp-mediated transport inhibited; antagonistic effects)
Monitor/Modify Tx
indapamide + pralsetinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Avoid/Use Alternative
amlodipine + propafenone
if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited, additive effects)
Monitor/Modify Tx
indapamide + propafenone
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + propafenone
monitor BP: combo may incr. risk of hypotension (additive effects)
Avoid/Use Alternative
telmisartan + quinapril
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + quinapril
monitor renal fxn, sodium, BP: combo may incr. risk of renal impairment, severe hyponatremia, hypotension (additive effects)
Avoid/Use Alternative
telmisartan + ramipril
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. ramipril levels, risk of hypotension, hyperkalemia, renal impairment without additional benefit, other adverse effects (mechanism unknown; additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + ramipril
monitor renal function, sodium, BP: combo may increase risk of renal impairment, severe hyponatremia, hypotension (additive effects)
Avoid/Use Alternative
telmisartan + relugolix
PROSTATE CANCER: may hold relugolix if telmisartan tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before telmisartan; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before telmisartan: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)
Avoid/Use Alternative
telmisartan + repotrectinib
avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + repotrectinib
monitor BP: combo may incr. repotrectinib levels, risk of adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)
Avoid/Use Alternative
telmisartan + rivaroxaban
avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)
Avoid/Use Alternative
amlodipine + simvastatin
use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)
Avoid/Use Alternative
telmisartan + sirolimus albumin-bound
avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + sirolimus albumin-bound
decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)
indapamide + sirolimus albumin-bound
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Avoid/Use Alternative
indapamide + sulfamethoxazole
avoid combo especially in elderly pts: combo may incr. risk of thrombocytopenia (mechanism unknown)
Avoid/Use Alternative
telmisartan + tacrolimus
consider alternative or monitor tacrolimus levels, ECG, BP, renal fxn, potassium, magnesium: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, hyperkalemia, other adverse effects; may decr. antihypertensive agent efficacy (P-gp-mediated transport inhibited, additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + tacrolimus
monitor tacrolimus levels, ECG, BP, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)
indapamide + tacrolimus
monitor tacrolimus levels, renal fxn, magnesium, BP: combo may incr. tacrolimus levels, risk of nephrotoxicity, hypomagnesemia, other adverse effects; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Avoid/Use Alternative
telmisartan + telmisartan
avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
indapamide + telmisartan
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
telmisartan + topotecan
avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited)
Avoid/Use Alternative
telmisartan + trandolapril
use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)
Monitor/Modify Tx
indapamide + trandolapril
monitor renal fxn, sodium: combo may incr. risk of renal impairment, severe hyponatremia (additive effects)
Avoid/Use Alternative
indapamide + tretinoin topical
consider alternative, especially if tretinoin topical cosmetic use: combo may incr. risk of phototoxicity or augment phototoxic reaction (possible additive effects)
Avoid/Use Alternative
telmisartan + valsartan
avoid combo: combo may incr. risk of hyperkalemia, renal impairment, other adverse effects (additive effects, duplicate therapy)
Monitor/Modify Tx
indapamide + valsartan
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Avoid/Use Alternative
telmisartan + venetoclax
monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + venetoclax
monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)
Avoid/Use Alternative
amlodipine + verapamil
avoid combo: combo may incr. verapamil levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited; duplicate therapy)
Monitor/Modify Tx
- abaloparatide
- abemaciclib
- abiraterone acetate
- acalabrutinib
- acarbose
- acetazolamide
- acyclovir
- adagrasib
- adefovir dipivoxil
- afatinib
- albuterol
- albuterol inhaled
- alfentanil
- alfuzosin
- allopurinol
- almotriptan
- aloe
- alogliptin
- alprostadil intracavernous
- amantadine
- amifostine
- amikacin inhaled
- amiodarone
- amitriptyline
- amoxapine
- amphetamine
- amphotericin
- anthrax immune globulin
- apalutamide
- apomorphine
- apraclonidine ophthalmic
- arformoterol inhaled
- aripiprazole bimonthly injection
- aripiprazole monthly injection
- aripiprazole oral
- armodafinil
- artemether/lumefantrine
- articaine
- asciminib
- asenapine
- asparaginase
- aspirin
- atazanavir
- atogepant
- atomoxetine
- atorvastatin
- atropine ophthalmic
- auranofin
- avanafil
- avapritinib
- axitinib
- balsalazide
- belzutifan
- benzphetamine
- berberine
- betamethasone
- betaxolol ophthalmic
- bethanechol
- bevacizumab
- bexagliflozin
- bexarotene
- bismuth subsalicylate
- bortezomib
- bosentan
- botulism immune globulin
- brexpiprazole
- brigatinib
- brimonidine ophthalmic
- brimonidine topical
- bromocriptine
- budesonide
- bumetanide
- bupivacaine
- bupivacaine liposomal
- buprenorphine
- bupropion
- burosumab
- butalbital
- butorphanol
- cabergoline
- cabozantinib
- caffeine
- caffeine citrate
- calcipotriene topical
- calcitriol
- calcitriol topical
- calcium acetate
- calcium carbonate
- calcium chloride
- calcium citrate
- calcium gluconate
- canagliflozin
- cannabis
- capecitabine
- capivasertib
- carbamazepine
- carboplatin
- carfilzomib
- cariprazine
- carteolol ophthalmic
- celecoxib
- cenobamate
- cetuximab
- chloramphenicol
- chloroprocaine
- chlorpromazine
- cholecalciferol (vitamin D3)
- cholestyramine
- cidofovir
- cilostazol
- cisplatin
- citalopram
- clarithromycin
- clindamycin
- clobazam
- clomipramine
- clonidine
- clozapine
- cobicistat
- cocaine
- coenzyme Q-10
- colesevelam
- colestipol
- colistimethate
- copanlisib
- copper histidinate
- corticotropin
- cortisone
- creatine
- crizotinib
- cyclophosphamide
- cyclosporine
- cytomegalovirus immune globulin
- dabrafenib
- danazol
- danshen
- dapagliflozin
- darbepoetin alfa
- darolutamide
- darunavir
- decitabine
- deferasirox
- deferoxamine
- deflazacort
- denileukin diftitox
- desflurane
- desipramine
- desmopressin
- desvenlafaxine
- dexamethasone
- dexlansoprazole
- dexmedetomidine
- dexmedetomidine injection
- dexmethylphenidate
- dextroamphetamine
- diazoxide
- dichlorphenamide
- diclofenac
- diclofenac topical
- dicloxacillin
- diethylpropion
- diflunisal
- digoxin
- dihydrocodeine
- dihydroergotamine
- dinutuximab
- dipyridamole
- disopyramide
- docetaxel
- dofetilide
- domperidone
- doxapram
- doxazosin
- doxepin
- doxercalciferol
- dronabinol
- dronedarone
- drospirenone (contraceptive)
- drospirenone (hormone replacement)
- droxidopa
- dulaglutide
- duloxetine
- echinacea
- edoxaban
- efavirenz
- elafibranor
- elagolix
- eletriptan
- emapalumab
- empagliflozin
- enasidenib
- encorafenib
- enfortumab vedotin
- entacapone
- entrectinib
- enzalutamide
- ephedra
- ephedrine injection
- ephedrine oral
- epinephrine
- epinephrine inhaled
- eplerenone
- epoetin alfa
- epoprostenol
- eptinezumab
- erenumab
- ergocalciferol (vitamin D2)
- ergotamine
- ertugliflozin
- erythromycin
- escitalopram
- esketamine
- eslicarbazepine acetate
- esomeprazole
- estetrol (contraceptive)
- estradiol (contraceptive)
- ethacrynic acid
- ethanol (alcoholic beverage)
- ethanol injection
- ethinyl estradiol (contraceptive)
- etodolac
- etrasimod
- etravirine
- etripamil nasal
- everolimus
- exenatide
- febuxostat
- fedratinib
- felbamate
- fenfluramine
- fenoprofen
- fentanyl
- ferumoxytol
- fexinidazole
- finerenone
- fingolimod
- flaxseed
- flibanserin
- fluconazole
- flucytosine
- fludrocortisone
- fluoxetine
- fluphenazine
- flurbiprofen
- fluvastatin
- fluvoxamine
- formoterol inhaled
- fosamprenavir
- foscarnet
- fosfomycin injection
- foslevodopa
- fosphenytoin
- fostamatinib
- fremanezumab
- frovatriptan
- fruquintinib
- furosemide
- galcanezumab
- ganciclovir
- garlic
- gentamicin
- gepirone
- gilteritinib
- ginkgo
- ginseng, Asian
- glimepiride
- glipizide
- glyburide
- glycerol phenylbutyrate
- griseofulvin
- guanfacine
- haloperidol
- heparin
- hoodia
- hydralazine
- hydrocortisone
- hydromorphone
- hydroxocobalamin IV
- ibrutinib
- ibuprofen
- ibuprofen lysine
- idelalisib
- ifosfamide
- iloperidone
- iloprost
- imatinib
- imipramine
- immune globulin
- indapamide
- indomethacin
- insulin
- iohexol
- iopamidol
- iothalamate meglumine
- irinotecan
- iron sucrose
- isoflurane
- isoproterenol
- isosorbide dinitrate
- isosorbide mononitrate
- itraconazole
- ivabradine
- ivosidenib
- ixabepilone
- ketamine
- ketoconazole
- ketoprofen
- ketorolac
- landiolol
- lanreotide
- lansoprazole
- lapatinib
- leflunomide
- lemborexant
- lenalidomide
- lenvatinib
- leucovorin
- levalbuterol inhaled
- levobunolol ophthalmic
- levodopa
- levoketoconazole
- levomilnacipran
- levorphanol
- levothyroxine
- licorice
- lidocaine
- linagliptin
- linezolid
- liothyronine
- liraglutide
- lisdexamfetamine
- lithium
- lixisenatide
- lomitapide
- lomustine
- lonafarnib
- lopinavir/ritonavir
- lorlatinib
- lovastatin
- loxapine
- lubiprostone
- lumacaftor/ivacaftor
- lumateperone
- lurasidone
- lurbinectedin
- luspatercept
- lutetium Lu 177 vipivotide tetraxetan
- magnesium citrate
- magnesium salicylate
- magnesium sulfate
- maraviroc
- mavacamten
- mavorixafor
- meclofenamate
- mefenamic acid
- meloxicam
- mepivacaine
- meropenem
- mesalamine
- mesalamine rectal
- metformin
- methamphetamine
- methazolamide
- methohexital
- methotrexate
- methoxy polyethylene glycol-epoetin beta
- methylene blue injection
- methylergonovine
- methylphenidate
- methylprednisolone
- methyltestosterone
- metoclopramide
- midazolam
- midodrine
- mifepristone
- miglitol
- milnacipran
- milrinone
- milsaperidone
- mirabegron
- mirtazapine
- mitapivat
- mitomycin
- mitotane
- mitoxantrone
- mobocertinib
- modafinil
- molindone
- morphine
- motixafortide
- mycophenolate mofetil
- nabumetone
- nafcillin
- nalbuphine
- naphazoline ophthalmic
- naproxen
- naratriptan
- nateglinide
- nattokinase
- naxitamab
- necitumumab
- nefazodone
- nelfinavir
- neomycin
- nevirapine
- niacin (vitamin B3)
- nilotinib
- niraparib
- nitric oxide
- nitrite
- nitroglycerin
- nitroprusside
- nortriptyline
- nusinersen
- obinutuzumab
- odevixibat
- olanzapine
- oliceridine
- olodaterol inhaled
- olsalazine
- olutasidenib
- omaveloxolone
- omeprazole
- opicapone
- opium
- osilodrostat
- oxaliplatin
- oxaprozin
- oxazepam
- oxcarbazepine
- oxymetazoline nasal
- oxymetazoline ophthalmic
- oxymetazoline topical
- oxymorphone
- oxytocin
- ozanimod
- pacritinib
- paliperidone
- palopegteriparatide
- pamidronate
- panitumumab
- pantoprazole
- paricalcitol
- paromomycin
- paroxetine
- patiromer
- pegloticase
- pemetrexed
- pemigatinib
- penicillamine
- pentamidine
- pentazocine
- pentobarbital
- pentostatin
- pentoxifylline
- perampanel
- perphenazine
- pexidartinib
- phendimetrazine
- phenelzine
- phenobarbital
- phentermine
- phenylephrine
- phenylephrine injection
- phenylephrine nasal
- phenylephrine ophthalmic
- phenylephrine rectal
- phenytoin
- pioglitazone
- piroxicam
- pitavastatin
- plazomicin
- polyethylene glycol
- polyethylene glycol/electrolytes
- polymyxin B
- ponatinib
- ponesimod
- posaconazole
- potassium acid phosphate
- potassium bicarbonate
- potassium citrate
- potassium iodide
- pramipexole
- pramlintide
- pravastatin
- prazosin
- prednisolone
- prednisone
- primidone
- probenecid
- procarbazine
- prochlorperazine
- promethazine
- propofol
- protriptyline
- pseudoephedrine
- quetiapine
- quinidine (antiarrhythmic)
- quinidine (CYP2D6 inhibitor)
- rabeprazole
- ramucirumab
- ranolazine
- rasagiline
- rasburicase
- red yeast rice
- regorafenib
- remifentanil
- remimazolam
- repaglinide
- Rho(D) immune globulin
- ribociclib
- rifabutin
- rifampin
- rifapentine
- rimegepant
- riociguat
- ripretinib
- risperidone
- ritonavir
- rituximab
- rizatriptan
- romidepsin
- ropeginterferon alfa-2b
- ropinirole
- ropivacaine
- rosiglitazone
- rosuvastatin
- rotigotine transdermal
- rufinamide
- sacituzumab govitecan
- sacubitril
- safinamide
- salmeterol inhaled
- salsalate
- sarilumab
- saxagliptin
- selegiline
- selegiline transdermal
- selinexor
- selpercatinib
- semaglutide
- sertraline
- sevoflurane
- sildenafil
- silodosin
- sincalide
- siponimod
- sirolimus
- sitagliptin
- sodium benzoate
- sodium ferric gluconate complex
- sodium phenylacetate
- sodium phenylbutyrate
- sodium polystyrene sulfonate
- sodium thiosulfate
- sorafenib
- sotagliflozin
- sotalol
- sotorasib
- spironolactone
- St. John's wort
- stiripentol
- streptomycin
- streptozocin
- succinylcholine
- sufentanil
- sulfate bowel prep
- sulindac
- sumatriptan
- sunitinib
- sunvozertinib
- suzetrigine
- tadalafil
- tafasitamab
- tagraxofusp
- talazoparib
- taletrectinib
- tamsulosin
- tapentadol
- taurine
- tazemetostat
- tecovirimat
- telavancin
- telotristat ethyl
- temsirolimus
- tenofovir alafenamide
- tenofovir disoproxil
- terazosin
- terbutaline
- teriflunomide
- teriparatide
- testosterone
- tetrahydrozoline ophthalmic
- thalidomide
- thioridazine
- thiothixene
- thyroid
- timolol ophthalmic
- tiopronin
- tipranavir
- tirzepatide
- tivozanib
- tizanidine
- tobramycin
- tobramycin inhaled
- tocilizumab
- tolcapone
- tolmetin
- tolvaptan
- topiramate
- toremifene
- torsemide
- tovorafenib
- tramadol
- trametinib
- tranylcypromine
- trazodone
- treprostinil
- triamcinolone
- triamterene
- triazolam
- trifluoperazine
- trimethoprim
- trimipramine
- tucatinib
- ubrogepant
- vaborbactam
- vaccinia immune globulin
- vadadustat
- valacyclovir
- valganciclovir
- valproic acid
- vamorolone
- vancomycin
- vandetanib
- vardenafil
- vasopressin
- vemurafenib
- venlafaxine
- vilanterol inhaled
- vilazodone
- viloxazine
- vinblastine
- vincristine
- vinorelbine
- vitamin A (retinol)
- voclosporin
- vonoprazan
- vorasidenib
- voriconazole
- vortioxetine
- vosoritide
- warfarin
- willow bark
- yohimbe
- zanubrutinib
- zavegepant
- ziprasidone
- ziv-aflibercept
- zoledronic acid
- zolmitriptan
- zonisamide
Monitor/Modify Tx
indapamide + abaloparatide
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
amlodipine + abemaciclib
monitor CBC: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, thrombosis, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + abiraterone acetate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + abiraterone acetate
monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + abiraterone acetate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + acalabrutinib
monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + acarbose
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + acetazolamide
monitor sodium, potassium: combo may incr. risk of severe hyponatremia, hypokalemia (additive effects)
Monitor/Modify Tx
indapamide + acyclovir
monitor renal fxn: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)
telmisartan + acyclovir
monitor renal fxn: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + adagrasib
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + adefovir dipivoxil
monitor renal fxn: combo may incr. adefovir levels, risk of nephrotoxicity, other adverse effects (renal excretion decreased, additive effects)
telmisartan + adefovir dipivoxil
monitor renal fxn: combo may incr. adefovir levels, risk of nephrotoxicity, other adverse effects (renal excretion decreased, additive effects)
Monitor/Modify Tx
telmisartan + afatinib
decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + albuterol
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + albuterol
monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + albuterol
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + albuterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + albuterol inhaled
monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + albuterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + alfentanil
monitor respiratory rate, BP; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and respiratory depression, psychomotor impairment, delayed recovery from anesthesia, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + alfentanil
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + alfentanil
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + alfuzosin
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + alfuzosin
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + alfuzosin
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
indapamide + allopurinol
monitor renal fxn, uric acid levels: combo may incr. risk of nephrotoxicity; may decr. allopurinol efficacy (additive effects; antagonistic effects)
telmisartan + allopurinol
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + almotriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + almotriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + almotriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + aloe
monitor potassium w/ aloe laxative doses: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
indapamide + alogliptin
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + alprostadil intracavernous
monitor BP: combo may increase risk of hypotension (additive effects)
indapamide + alprostadil intracavernous
monitor BP: combo may increase risk of hypotension, including orthostasis (additive effects)
telmisartan + alprostadil intracavernous
monitor BP: combo may increase risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + amantadine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + amantadine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + amantadine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + amifostine
D/C (lev)amlodipine 24h before amifostine admin.; monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)
indapamide + amifostine
D/C indapamide 24h before amifostine admin.; monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
telmisartan + amifostine
D/C telmisartan 24h before amifostine admin.; monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)
Monitor/Modify Tx
indapamide + amikacin inhaled
monitor renal fxn, ototoxicity: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
telmisartan + amikacin inhaled
monitor renal fxn, ototoxicity: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + amiodarone
monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + amitriptyline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + amitriptyline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + amitriptyline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + amoxapine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + amoxapine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + amoxapine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + amphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + amphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + amphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + amphotericin
monitor renal fxn, magnesium, potassium, ECG: combo may incr. risk of nephrotoxicity, hypomagnesemia, hypokalemia, cardiac arrhythmias (additive effects)
telmisartan + amphotericin
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
indapamide + anthrax immune globulin
monitor renal fxn; use lowest anthrax immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + anthrax immune globulin
monitor renal fxn; use lowest anthrax immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + apalutamide
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + apomorphine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + apomorphine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
telmisartan + apomorphine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + apraclonidine ophthalmic
monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of hypotension (additive effects)
indapamide + apraclonidine ophthalmic
monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + apraclonidine ophthalmic
monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + arformoterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + arformoterol inhaled
monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + arformoterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + aripiprazole bimonthly injection
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + aripiprazole bimonthly injection
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + aripiprazole bimonthly injection
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + aripiprazole monthly injection
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + aripiprazole monthly injection
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + aripiprazole monthly injection
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + aripiprazole oral
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + aripiprazole oral
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + aripiprazole oral
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + armodafinil
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced, antagonistic effects)
indapamide + armodafinil
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + armodafinil
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + artemether/ lumefantrine
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + articaine
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + articaine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + articaine
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + asciminib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + asciminib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + asciminib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + asenapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + asenapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + asenapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
indapamide + asparaginase
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + aspirin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + aspirin
monitor BP, renal fxn: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + aspirin
monitor BP, renal fxn: combo may incr. risk of renal impairment; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + atazanavir
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + atogepant
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + atogepant
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + atogepant
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + atomoxetine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + atomoxetine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + atomoxetine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
telmisartan + atorvastatin
monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + atropine ophthalmic
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + atropine ophthalmic
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + atropine ophthalmic
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + auranofin
monitor renal fxn: combo may incr. auranofin levels, risk of nephrotoxicity, other adverse effects (additive effects)
telmisartan + auranofin
monitor renal fxn: combo may incr. auranofin levels, risk of nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + avanafil
monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension (including orthostasis, syncope), priapism, other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + avanafil
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + avanafil
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + avapritinib
monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + axitinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + axitinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + axitinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + balsalazide
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + balsalazide
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + belzutifan
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + benzphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + benzphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + benzphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + berberine
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + berberine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + berberine
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + betamethasone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + betamethasone
monitor BP, potassium: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + betamethasone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + betaxolol ophthalmic
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + betaxolol ophthalmic
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + betaxolol ophthalmic
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + bethanechol
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + bethanechol
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + bethanechol
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + bevacizumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + bevacizumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + bevacizumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + bexagliflozin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + bexagliflozin
monitor glucose, BP: combo may incr. risk of hypotension, including orthostasis; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)
telmisartan + bexagliflozin
monitor glucose, BP: combo may decr. bexagliflozin levels, efficacy; may incr. risk of hypotension, including orthostasis (UGT induced; additive effects)
Monitor/Modify Tx
amlodipine + bexarotene
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + bismuth subsalicylate
monitor BP w/ high-dose bismuth subsalicylate: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + bismuth subsalicylate
monitor BP w/ high-dose bismuth subsalicylate: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + bismuth subsalicylate
monitor BP w/ high-dose bismuth subsalicylate: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + bortezomib
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + bortezomib
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
telmisartan + bortezomib
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + bosentan
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
indapamide + botulism immune globulin
monitor renal fxn; use lowest botulism immune globulin concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + botulism immune globulin
monitor renal fxn; use lowest botulism immune globulin concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + brexpiprazole
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + brexpiprazole
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + brexpiprazole
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + brigatinib
monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced, antagonistic effects)
indapamide + brigatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + brigatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + brimonidine ophthalmic
monitor BP if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of hypotension (additive effects)
indapamide + brimonidine ophthalmic
monitor BP if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of hypotension, including orthostasis (additive effects)
telmisartan + brimonidine ophthalmic
monitor BP if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + brimonidine topical
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + brimonidine topical
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + brimonidine topical
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + bromocriptine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + bromocriptine
monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)
telmisartan + bromocriptine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + budesonide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + budesonide
monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + budesonide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + bumetanide
monitor renal fxn, electrolytes: combo may incr. risk of renal impairment, severe hyponatremia, hypokalemia, hypomagnesemia, other adverse effects (additive effects, duplicate therapy)
telmisartan + bumetanide
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Monitor/Modify Tx
amlodipine + bupivacaine
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + bupivacaine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + bupivacaine
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + bupivacaine liposomal
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + bupivacaine liposomal
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + bupivacaine liposomal
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + buprenorphine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + buprenorphine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + buprenorphine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + bupropion
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + bupropion
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + bupropion
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + burosumab
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
amlodipine + butalbital
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
indapamide + butalbital
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + butorphanol
monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)
indapamide + butorphanol
monitor BP; consider incr. indapamide dose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + butorphanol
monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)
Monitor/Modify Tx
amlodipine + cabergoline
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + cabergoline
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + cabergoline
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + cabozantinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + cabozantinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + cabozantinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + caffeine
monitor BP; avoid excessive caffeine intake: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + caffeine
monitor BP; avoid excessive caffeine intake: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + caffeine
monitor BP; avoid excessive caffeine intake: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + caffeine citrate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + caffeine citrate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + caffeine citrate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + calcipotriene topical
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
indapamide + calcitriol
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
indapamide + calcitriol topical
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
indapamide + calcium acetate
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
indapamide + calcium carbonate
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
indapamide + calcium chloride
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
indapamide + calcium citrate
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
indapamide + calcium gluconate
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
amlodipine + canagliflozin
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + canagliflozin
monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)
telmisartan + canagliflozin
monitor BP, glucose and adjust dose as follows: if eGFR >60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day; if eGFR >60 and usual dose 200 mg, incr. canagliflozin dose to 300 mg/day; if eGFR <60 and usual dose 100 mg, incr. canagliflozin dose to 200 mg/day and consider additional antihyperglycemic agent: combo may decr. canagliflozin levels, efficacy; may incr. risk of hypotension, including orthostasis, syncope (UGT induced; additive effects)
Monitor/Modify Tx
amlodipine + cannabis
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
indapamide + cannabis
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
telmisartan + cannabis
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
Monitor/Modify Tx
indapamide + capecitabine
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + capecitabine
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + capivasertib
monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + carbamazepine
monitor BP, carbamazepine levels: combo may incr. carbamazepine levels, risk of adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)
indapamide + carbamazepine
monitor sodium: combo may incr. risk of severe hyponatremia, seizures (additive effects)
Monitor/Modify Tx
indapamide + carboplatin
monitor CBC, renal fxn, magnesium: combo may incr. carboplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, hypomagnesemia, auditory, vestibular, other adverse effects (additive effects)
telmisartan + carboplatin
monitor CBC, renal fxn, ototoxicity: combo may incr. carboplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + carfilzomib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + carfilzomib
monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + carfilzomib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + cariprazine
monitor BP: combo may incr. cariprazine and active metabolite levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + cariprazine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + cariprazine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + carteolol ophthalmic
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + carteolol ophthalmic
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + carteolol ophthalmic
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + celecoxib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + celecoxib
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + celecoxib
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + cenobamate
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
indapamide + cetuximab
monitor potassium, magnesium: combo may incr. risk of hypokalemia, hypomagnesemia (additive effects)
Monitor/Modify Tx
amlodipine + chloramphenicol
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + chloroprocaine
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + chloroprocaine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + chloroprocaine
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + chlorpromazine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + chlorpromazine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + chlorpromazine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
indapamide + cholecalciferol (vitamin D3)
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
indapamide + cholestyramine
give thiazide >4h before or >4-6h after bile acid binding resin doses: combo may decr. thiazide levels, efficacy (absorption decreased)
Monitor/Modify Tx
indapamide + cidofovir
monitor CBC, renal fxn: combo may incr. cidofovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
telmisartan + cidofovir
monitor CBC, renal fxn: combo may incr. cidofovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + cilostazol
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + cilostazol
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + cilostazol
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + cisplatin
monitor CBC, renal fxn, electrolytes, ototoxicity: combo may incr. cisplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, hypokalemia, severe hyponatremia, hypomagnesemia, tetany, auditory, vestibular, other adverse effects (additive effects)
telmisartan + cisplatin
monitor CBC, renal fxn, ototoxicity: combo may incr. cisplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
indapamide + citalopram
monitor sodium: combo may incr. risk of severe hyponatremia (additive effects)
Monitor/Modify Tx
amlodipine + clarithromycin
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + clindamycin
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + clindamycin
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + clobazam
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + clomipramine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + clomipramine
monitor BP, sodium: combo may incr. risk of hypotension (including orthostasis), severe hyponatremia (additive effects)
telmisartan + clomipramine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + clonidine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + clonidine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + clonidine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + clozapine
monitor ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + clozapine
monitor BP, HR: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + clozapine
monitor BP, HR: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + cobicistat
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + cocaine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + cocaine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + cocaine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + coenzyme Q-10
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + coenzyme Q-10
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + coenzyme Q-10
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + colesevelam
monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + colestipol
give thiazide >4h before or >4-6h after bile acid binding resin doses: combo may decr. thiazide levels, efficacy (absorption decreased)
Monitor/Modify Tx
indapamide + colistimethate
monitor renal fxn: combo may incr. colistimethate levels, risk of nephrotoxicity, other adverse effects (additive effects)
telmisartan + colistimethate
monitor renal fxn: combo may incr. colistimethate levels, risk of nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + copanlisib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects, copanlisib may cause infusion-related HTN)
indapamide + copanlisib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects, copanlisib may cause infusion-related HTN)
telmisartan + copanlisib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects, copanlisib may cause infusion-related HTN)
Monitor/Modify Tx
indapamide + copper histidinate
monitor renal fxn, electrolytes: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + copper histidinate
monitor renal fxn, electrolytes: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + corticotropin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + corticotropin
monitor BP, potassium: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + corticotropin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + cortisone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + cortisone
monitor BP, potassium: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + cortisone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + creatine
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + creatine
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
indapamide + crizotinib
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
indapamide + cyclophosphamide
monitor CBC, renal, cardiac fxn, sodium: combo may incr. cyclophosphamide levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, severe hyponatremia (including life-threatening), other adverse effects (additive effects)
telmisartan + cyclophosphamide
monitor CBC, renal, cardiac fxn: combo may incr. cyclophosphamide levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)
Caution Advised
amlodipine + cyclophosphamide
caution advised: combo may decr. cyclophosphamide active metabolite levels, efficacy (hepatic metabolism possibly inhibited, decr. conversion to active metabolite)
Monitor/Modify Tx
amlodipine + cyclosporine
monitor cyclosporine levels, renal fxn, BP: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)
indapamide + cyclosporine
monitor renal fxn, magnesium, BP: combo may incr. risk of nephrotoxicity, hypomagnesemia, seizures; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + cyclosporine
monitor cyclosporine levels, renal fxn, potassium, BP: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, hyperkalemia, other adverse effects; may decr. antihypertensive agent efficacy (P-gp-mediated transport inhibited, additive effects; antagonistic effects)
Monitor/Modify Tx
indapamide + cytomegalovirus immune globulin
monitor renal fxn; use lowest cytomegalovirus immune globulin concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + cytomegalovirus immune globulin
monitor renal fxn; use lowest cytomegalovirus immune globulin concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + dabrafenib
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + danazol
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + danazol
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + danazol
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + danshen
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + dapagliflozin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + dapagliflozin
monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)
telmisartan + dapagliflozin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + darbepoetin alfa
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + darbepoetin alfa
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + darbepoetin alfa
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + darolutamide
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Caution Advised
telmisartan + darolutamide
if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + darunavir
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + decitabine
monitor potassium w/ IV decitabine use: combo may incr. risk of hypokalemia (additive effects)
telmisartan + decitabine
monitor potassium w/ IV decitabine use: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
indapamide + deferasirox
monitor CBC, renal fxn, ototoxicity: combo may incr. deferasirox levels, risk of myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
telmisartan + deferasirox
monitor CBC, renal fxn, ototoxicity: combo may incr. deferasirox levels, risk of myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
indapamide + deferoxamine
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + deferoxamine
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + deflazacort
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + deflazacort
monitor BP, potassium: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + deflazacort
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + denileukin diftitox
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + denileukin diftitox
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + denileukin diftitox
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + desflurane
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + desflurane
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + desflurane
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + desipramine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + desipramine
monitor BP, sodium: combo may incr. risk of hypotension (including orthostasis), severe hyponatremia (additive effects)
telmisartan + desipramine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + desmopressin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + desmopressin
monitor BP, sodium: combo may incr. risk of severe hyponatremia, including life-threatening; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + desmopressin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + desvenlafaxine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + desvenlafaxine
monitor sodium, BP: combo may incr. risk of severe hyponatremia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + desvenlafaxine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + dexamethasone
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced, antagonistic effects)
indapamide + dexamethasone
monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + dexamethasone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + dexlansoprazole
monitor magnesium, especially w/ dexlansoprazole tx >3mo: combo may incr. risk of hypomagnesemia, cardiac arrhythmias, tetany, seizures (additive effects)
Monitor/Modify Tx
amlodipine + dexmedetomidine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + dexmedetomidine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + dexmedetomidine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + dexmedetomidine injection
monitor BP: combo may incr. risk of severe or life-threatening hypotension (additive effects)
indapamide + dexmedetomidine injection
monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis (additive effects)
telmisartan + dexmedetomidine injection
monitor BP: combo may incr. risk of severe or life-threatening hypotension (additive effects)
Monitor/Modify Tx
amlodipine + dexmethylphenidate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + dexmethylphenidate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + dexmethylphenidate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + dextroamphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + dextroamphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + dextroamphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + diazoxide
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + diazoxide
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + diazoxide
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + dichlorphenamide
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + diclofenac
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + diclofenac
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + diclofenac
monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + diclofenac topical
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + diclofenac topical
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + diclofenac topical
monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + dicloxacillin
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + diethylpropion
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + diethylpropion
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + diethylpropion
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + diflunisal
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + diflunisal
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + diflunisal
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
indapamide + digoxin
monitor electrolytes: combo may incr. risk of digoxin toxicity, cardiac arrhythmias (electrolyte abnormalities may incr. digoxin sensitivity)
telmisartan + digoxin
monitor digoxin levels, HR; decr. digoxin frequency or dose by 15-30%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + dihydrocodeine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + dihydrocodeine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + dihydrocodeine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + dihydroergotamine
monitor BP: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)
indapamide + dihydroergotamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + dihydroergotamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + dinutuximab
monitor BP: combo may incr. risk of severe hypotension (additive effects)
indapamide + dinutuximab
monitor BP, sodium, potassium: combo may incr. risk of severe hypotension (including orthostasis), severe hyponatremia, hypokalemia (additive effects)
telmisartan + dinutuximab
monitor BP: combo may incr. risk of severe hypotension (additive effects)
Monitor/Modify Tx
amlodipine + dipyridamole
monitor BP: combo may incr. risk of severe hypotension (additive effects)
indapamide + dipyridamole
monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
telmisartan + dipyridamole
monitor BP: combo may incr. risk of severe hypotension (additive effects)
Monitor/Modify Tx
amlodipine + disopyramide
monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + docetaxel
monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + dofetilide
monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
indapamide + dofetilide
monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (electrolyte abnormalities)
Monitor/Modify Tx
amlodipine + domperidone
monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + doxapram
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + doxapram
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + doxapram
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + doxazosin
monitor BP, especially during doxazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + doxazosin
monitor BP, especially during doxazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + doxazosin
monitor BP, especially during doxazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + doxepin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + doxepin
monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
telmisartan + doxepin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
indapamide + doxercalciferol
monitor calcium: combo may incr. risk of hypercalcemia, cardiac arrhythmias, seizures (additive effects)
Monitor/Modify Tx
amlodipine + dronabinol
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
indapamide + dronabinol
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
telmisartan + dronabinol
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
Monitor/Modify Tx
amlodipine + dronedarone
monitor ECG, BP, HR; decr. (lev)amlodipine start dose: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
telmisartan + drospirenone (contraceptive)
monitor potassium: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
telmisartan + drospirenone (hormone replacement)
monitor potassium: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
amlodipine + droxidopa
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
indapamide + droxidopa
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
telmisartan + droxidopa
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
Monitor/Modify Tx
indapamide + dulaglutide
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + duloxetine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + duloxetine
monitor BP, sodium: combo may incr. risk of severe hyponatremia, hypotension, including orthostasis (additive effects)
telmisartan + duloxetine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + echinacea
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
telmisartan + edoxaban
monitor bleeding s/sx: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + efavirenz
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + elafibranor
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + elagolix
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + eletriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + eletriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + eletriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + emapalumab
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + empagliflozin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + empagliflozin
monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)
telmisartan + empagliflozin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + enasidenib
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + encorafenib
monitor ECG, BP: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)
Monitor/Modify Tx
telmisartan + enfortumab vedotin
if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + entacapone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + entacapone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + entacapone
monitor BP: combo may decr. entacapone levels, efficacy; may incr. risk of hypotension, including orthostasis, syncope (UGT induced; additive effects)
Monitor/Modify Tx
amlodipine + entrectinib
monitor ECG, CBC, BP: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, hypotension, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + entrectinib
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + entrectinib
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + enzalutamide
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + ephedra
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ephedra
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ephedra
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + ephedrine injection
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ephedrine injection
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ephedrine injection
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + ephedrine oral
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ephedrine oral
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ephedrine oral
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + epinephrine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + epinephrine
monitor BP, potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias; may decr. efficacy of both drugs (additive effects; antagonistic effects)
telmisartan + epinephrine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + epinephrine inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + epinephrine inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + epinephrine inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + eplerenone
monitor potassium: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)
telmisartan + eplerenone
monitor potassium, renal fxn: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
amlodipine + epoetin alfa
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + epoetin alfa
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + epoetin alfa
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + epoprostenol
monitor BP: combo may incr. risk of severe hypotension (additive effects)
indapamide + epoprostenol
monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
telmisartan + epoprostenol
monitor BP: combo may incr. risk of severe hypotension (additive effects)
Monitor/Modify Tx
amlodipine + eptinezumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + eptinezumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + eptinezumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + erenumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + erenumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + erenumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + ergocalciferol (vitamin D2)
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
amlodipine + ergotamine
monitor BP: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)
indapamide + ergotamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ergotamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + ertugliflozin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + ertugliflozin
monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)
telmisartan + ertugliflozin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + erythromycin
monitor ECG: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + escitalopram
monitor sodium: combo may incr. risk of severe hyponatremia (additive effects)
Monitor/Modify Tx
amlodipine + esketamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + esketamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + esketamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + eslicarbazepine acetate
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
indapamide + eslicarbazepine acetate
monitor sodium: combo may incr. risk of severe hyponatremia (including life-threatening), seizures (additive effects)
Monitor/Modify Tx
indapamide + esomeprazole
monitor magnesium, especially w/ esomeprazole tx >3mo: combo may incr. risk of hypomagnesemia, cardiac arrhythmias, tetany, seizures (additive effects)
Monitor/Modify Tx
amlodipine + estetrol (contraceptive)
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + estetrol (contraceptive)
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + estetrol (contraceptive)
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + estradiol (contraceptive)
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + estradiol (contraceptive)
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + estradiol (contraceptive)
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + ethacrynic acid
monitor renal fxn, electrolytes: combo may incr. risk of renal impairment, severe hyponatremia, hypokalemia, hypomagnesemia, other adverse effects (additive effects, duplicate therapy)
telmisartan + ethacrynic acid
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Monitor/Modify Tx
amlodipine + ethanol (alcoholic beverage)
monitor BP: combo may alter BP control, initially incr. risk of severe hypotension, followed by HTN (additive effects, antagonistic effects, acute alcohol intake may have biphasic effects on blood pressure; chronic alcohol use may further increase HTN risk)
indapamide + ethanol (alcoholic beverage)
monitor BP: combo may alter BP control, initially incr. risk of severe hypotension (including orthostasis), followed by HTN (additive effects, antagonistic effects, acute alcohol intake may have biphasic effects on blood pressure; chronic alcohol use may further increase HTN risk)
telmisartan + ethanol (alcoholic beverage)
monitor BP: combo may alter BP control, initially incr. risk of severe hypotension, followed by HTN (additive effects, antagonistic effects, acute alcohol intake may have biphasic effects on blood pressure; chronic alcohol use may further increase HTN risk)
Monitor/Modify Tx
amlodipine + ethanol injection
monitor BP: combo may incr. risk of severe hypotension (additive effects)
indapamide + ethanol injection
monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
telmisartan + ethanol injection
monitor BP: combo may incr. risk of severe hypotension (additive effects)
Monitor/Modify Tx
amlodipine + ethinyl estradiol (contraceptive)
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ethinyl estradiol (contraceptive)
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ethinyl estradiol (contraceptive)
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + etodolac
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + etodolac
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + etodolac
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + etrasimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + etrasimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + etrasimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + etravirine
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
indapamide + etripamil nasal
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + etripamil nasal
monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)
Monitor/Modify Tx
amlodipine + everolimus
TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)
telmisartan + everolimus
TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
indapamide + exenatide
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + febuxostat
monitor uric acid levels: combo may decr. febuxostat efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + fedratinib
if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs: combo may incr. fedratinib levels, risk of myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + felbamate
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + fenfluramine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + fenfluramine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + fenfluramine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + fenoprofen
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + fenoprofen
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + fenoprofen
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + fentanyl
monitor respiratory rate, BP; consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + fentanyl
monitor BP; consider incr. indapamide dose: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + fentanyl
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + ferumoxytol
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + ferumoxytol
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + ferumoxytol
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + fexinidazole
monitor BP: combo may decr. fexinidazole active metabolite levels, efficacy; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolites; hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + finerenone
monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)
telmisartan + finerenone
monitor potassium: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
amlodipine + fingolimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + fingolimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + fingolimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + flaxseed
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + flaxseed
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + flaxseed
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + flibanserin
monitor BP, especially if flibanserin also combined w/ other weak CYP3A4 inhibitors: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + flibanserin
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
telmisartan + flibanserin
monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)
Monitor/Modify Tx
amlodipine + fluconazole
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism possibly inhibited)
Monitor/Modify Tx
indapamide + flucytosine
monitor CBC, renal fxn, flucytosine levels: combo may incr. flucytosine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
telmisartan + flucytosine
monitor CBC, renal fxn, flucytosine levels: combo may incr. flucytosine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + fludrocortisone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + fludrocortisone
monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + fludrocortisone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + fluoxetine
monitor sodium: combo may incr. risk of severe hyponatremia (additive effects)
Monitor/Modify Tx
amlodipine + fluphenazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + fluphenazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + fluphenazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + flurbiprofen
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + flurbiprofen
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + flurbiprofen
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
telmisartan + fluvastatin
monitor CK, myopathy sx: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited)
Monitor/Modify Tx
indapamide + fluvoxamine
monitor sodium: combo may incr. risk of severe hyponatremia (additive effects)
Monitor/Modify Tx
amlodipine + formoterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + formoterol inhaled
monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + formoterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + fosamprenavir
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + foscarnet
monitor CBC, renal fxn, magnesium, potassium, ECG: combo may incr. foscarnet levels, risk of myelosuppression, nephrotoxicity, hypomagnesemia, hypokalemia, QT prolongation, cardiac arrhythmias, tetany, seizures, other adverse effects (additive effects)
telmisartan + foscarnet
monitor CBC, renal fxn: combo may incr. foscarnet levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
indapamide + fosfomycin injection
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + foslevodopa
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + foslevodopa
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + foslevodopa
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + fosphenytoin
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + fostamatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + fostamatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + fostamatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + fremanezumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + fremanezumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + fremanezumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + frovatriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + frovatriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + frovatriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + fruquintinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + fruquintinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + fruquintinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + furosemide
monitor renal fxn, electrolytes: combo may incr. risk of renal impairment, severe hyponatremia, hypokalemia, hypomagnesemia, other adverse effects (additive effects, duplicate therapy)
telmisartan + furosemide
monitor renal fxn; consider decr. dose of one or both drugs: combo may incr. risk of renal impairment (additive effects)
Monitor/Modify Tx
amlodipine + galcanezumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + galcanezumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + galcanezumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + ganciclovir
monitor CBC, renal fxn: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
telmisartan + ganciclovir
monitor CBC, renal fxn: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + garlic
monitor BP w/ supplemental garlic; dietary intake OK: combo may decr. (lev)amlodipine levels, efficacy; may incr. risk of hypotension (hepatic metabolism induced; additive effects)
indapamide + garlic
monitor BP w/ supplemental garlic; dietary intake OK: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + garlic
monitor BP w/ supplemental garlic; dietary intake OK: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + gentamicin
monitor gentamicin levels, renal fxn, magnesium, ototoxicity: combo may incr. gentamicin levels, risk of nephrotoxicity, hypomagnesemia, tetany, auditory, vestibular, other adverse effects (additive effects)
telmisartan + gentamicin
monitor gentamicin levels, renal fxn, ototoxicity: combo may incr. gentamicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + gepirone
monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + gilteritinib
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + gilteritinib
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + gilteritinib
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + ginkgo
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + ginseng, Asian
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
indapamide + glimepiride
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
telmisartan + glimepiride
monitor glucose: combo may incr. risk of hypoglycemia (additive effects)
Monitor/Modify Tx
indapamide + glipizide
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
telmisartan + glipizide
monitor glucose: combo may incr. risk of hypoglycemia (additive effects)
Monitor/Modify Tx
indapamide + glyburide
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
telmisartan + glyburide
monitor glucose: combo may incr. risk of hypoglycemia (additive effects)
Monitor/Modify Tx
amlodipine + glycerol phenylbutyrate
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + griseofulvin
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + guanfacine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + guanfacine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + guanfacine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + haloperidol
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + haloperidol
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + haloperidol
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
telmisartan + heparin
monitor potassium: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
amlodipine + hoodia
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + hoodia
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + hoodia
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + hydralazine
monitor BP: combo may incr. risk of severe hypotension (additive effects)
indapamide + hydralazine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
telmisartan + hydralazine
monitor BP: combo may incr. risk of severe hypotension (additive effects)
Monitor/Modify Tx
amlodipine + hydrocortisone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + hydrocortisone
monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + hydrocortisone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + hydromorphone
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + hydromorphone
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + hydromorphone
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + hydroxocobalamin IV
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + hydroxocobalamin IV
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + hydroxocobalamin IV
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + ibrutinib
monitor BP; consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)
indapamide + ibrutinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ibrutinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + ibuprofen
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ibuprofen
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + ibuprofen
monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
indapamide + ibuprofen lysine
monitor renal fxn: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + ibuprofen lysine
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Monitor/Modify Tx
amlodipine + idelalisib
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + ifosfamide
monitor CBC, sodium, renal, cardiac fxn: combo may incr. ifosfamide levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, severe hyponatremia, other adverse effects (additive effects)
telmisartan + ifosfamide
monitor CBC, renal, cardiac fxn: combo may incr. ifosfamide levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + iloperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + iloperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + iloperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + iloprost
monitor BP; consider holding amlodipine during iloprost admin.: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
indapamide + iloprost
monitor BP; consider holding indapamide during iloprost admin.: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
telmisartan + iloprost
monitor BP; consider holding telmisartan during iloprost admin.: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + imatinib
monitor CBC: combo may incr. imatinib levels, risk of myelosuppression, other adverse effects (hepatic metabolism possibly inhibited)
Monitor/Modify Tx
amlodipine + imipramine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + imipramine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + imipramine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
indapamide + immune globulin
monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + immune globulin
monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
telmisartan + indapamide
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Monitor/Modify Tx
amlodipine + indomethacin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + indomethacin
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + indomethacin
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
indapamide + insulin
monitor glucose, potassium: combo may incr. risk of hypokalemia; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)
telmisartan + insulin
monitor glucose: combo may incr. risk of hypoglycemia (additive effects)
Monitor/Modify Tx
indapamide + iohexol
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + iohexol
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
indapamide + iopamidol
if IV iopamidol use, monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + iopamidol
if IV iopamidol use, monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
indapamide + iothalamate meglumine
if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + iothalamate meglumine
if IV iothalamate meglumine use, monitor renal function; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
telmisartan + irinotecan
monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (BCRP-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + iron sucrose
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + iron sucrose
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + iron sucrose
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + isoflurane
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + isoflurane
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + isoflurane
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + isoproterenol
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + isosorbide dinitrate
monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)
indapamide + isosorbide dinitrate
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
telmisartan + isosorbide dinitrate
monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)
Monitor/Modify Tx
amlodipine + isosorbide mononitrate
monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)
indapamide + isosorbide mononitrate
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
telmisartan + isosorbide mononitrate
monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)
Monitor/Modify Tx
amlodipine + itraconazole
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + ivabradine
monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + ivosidenib
monitor ECG, BP: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + ixabepilone
monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + ketamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ketamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ketamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + ketoconazole
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + ketoprofen
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ketoprofen
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + ketoprofen
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + ketorolac
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ketorolac
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + ketorolac
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + landiolol
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + landiolol
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + landiolol
monitor BP, potassium, especially if renal impairment: combo may incr. risk of hypotension, hyperkalemia (additive effects)
Monitor/Modify Tx
amlodipine + lanreotide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + lanreotide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + lanreotide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + lansoprazole
monitor magnesium, especially w/ lansoprazole tx >3mo: combo may incr. risk of hypomagnesemia, cardiac arrhythmias, tetany, seizures (additive effects)
Monitor/Modify Tx
telmisartan + lapatinib
monitor ECG: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (BCRP-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + leflunomide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + leflunomide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + leflunomide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + lemborexant
adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + lenalidomide
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + lenvatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + lenvatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + lenvatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + leucovorin
monitor calcium: combo may increase risk of hypercalcemia (additive effects, (levo)leucovorin injection contains calcium)
Monitor/Modify Tx
amlodipine + levalbuterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + levalbuterol inhaled
monitor BP, potassium: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + levalbuterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + levobunolol ophthalmic
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + levobunolol ophthalmic
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + levobunolol ophthalmic
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + levodopa
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + levodopa
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + levodopa
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + levoketoconazole
monitor BP, consider monitoring ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + levomilnacipran
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + levomilnacipran
monitor BP, sodium: combo may incr. risk of severe hyponatremia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + levomilnacipran
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + levorphanol
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + levorphanol
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + levorphanol
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + levothyroxine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + levothyroxine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + levothyroxine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + licorice
monitor BP w/ large amounts of licorice: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + licorice
monitor BP, potassium w/ large amounts of licorice: combo may decr. antihypertensive agent efficacy; may incr. risk of hypokalemia (additive effects; antagonistic effects)
telmisartan + licorice
monitor BP w/ large amounts of licorice: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + lidocaine
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + lidocaine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + lidocaine
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + linagliptin
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + linezolid
monitor sodium: combo may incr. risk of severe hyponatremia (additive effects)
Monitor/Modify Tx
amlodipine + liothyronine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + liothyronine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + liothyronine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + liraglutide
monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + lisdexamfetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + lisdexamfetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + lisdexamfetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + lithium
monitor lithium levels, renal fxn; consider decr. lithium start dose: combo may incr. lithium levels, risk of nephrotoxicity, other adverse effects (additive effects)
telmisartan + lithium
monitor lithium levels, renal fxn; consider decr. lithium start dose: combo may incr. lithium levels, risk of nephrotoxicity, other adverse effects (additive effects)
Caution Advised
amlodipine + lithium
caution advised: combo may incr. risk of neurotoxicity (mechanism unknown)
Monitor/Modify Tx
indapamide + lixisenatide
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + lomitapide
ADULT PATIENTS: if patient on stable amlodipine dose and starting lomitapide, adjust max lomitapide dose to 30 mg/day; if patient on stable lomitapide dose and starting amlodipine, decr. lomitapide dose by 50% and adjust max lomitapide dose to 30 mg/day; PEDIATRIC PATIENTS: if patient on stable amlodipine dose and starting lomitapide, adjust max lomitapide dose to 10 mg/day if 2-10 yo or 20 mg/day if 11-17 yo; if patient on stable lomitapide dose and starting amlodipine, decr. lomitapide dose by 50% and adjust max lomitapide dose to 10 mg/day if 2-10 yo or 20 mg/day if 11-17 yo: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + lomustine
monitor CBC, renal fxn: combo may incr. lomustine levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)
telmisartan + lomustine
monitor CBC, renal fxn: combo may incr. lomustine levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + lonafarnib
monitor BP; consider monitoring HR, ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + lopinavir/ ritonavir
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + lorlatinib
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced, antagonistic effects)
indapamide + lorlatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + lorlatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + lovastatin
monitor CK, myopathy sx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + loxapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + loxapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + loxapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + lubiprostone
monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)
indapamide + lubiprostone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + lubiprostone
monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)
Monitor/Modify Tx
amlodipine + lumacaftor/ ivacaftor
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced, antagonistic effects)
indapamide + lumacaftor/ ivacaftor
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + lumacaftor/ ivacaftor
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + lumateperone
monitor ECG, BP: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + lumateperone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + lumateperone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + lurasidone
monitor ECG, BP; consider lowest lurasidone start dose, titrate slowly: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + lurasidone
monitor BP; consider lowest lurasidone start dose, titrate slowly: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + lurasidone
monitor BP; consider lowest lurasidone start dose, titrate slowly: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + lurbinectedin
monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + luspatercept
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + luspatercept
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + luspatercept
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + lutetium Lu 177 vipivotide tetraxetan
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + lutetium Lu 177 vipivotide tetraxetan
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
indapamide + magnesium citrate
monitor renal fxn, sodium, potassium, consider monitoring ECG if magnesium citrate bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, renal impairment, severe hyponatremia, seizures (additive effects)
telmisartan + magnesium citrate
monitor renal fxn, especially if magnesium citrate bowel prep use: combo may incr. risk of renal impairment (additive effects)
Monitor/Modify Tx
amlodipine + magnesium salicylate
monitor BP w/ high-dose magnesium salicylate: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + magnesium salicylate
monitor renal fxn, BP w/ high-dose magnesium salicylate: combo may incr. risk of renal impairment; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + magnesium salicylate
monitor renal fxn, BP w/ high-dose magnesium salicylate: combo may incr. risk of renal impairment; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + magnesium sulfate
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + magnesium sulfate
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + magnesium sulfate
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + maraviroc
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + maraviroc
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + maraviroc
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + mavacamten
monitor BP, cardiac fxn incl. LVEF, especially during amlodipine initiation/titration: combo may incr. mavacamten levels, risk of left ventricular systolic dysfunction, heart failure, other adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced; additive negative inotropic effects)
Monitor/Modify Tx
telmisartan + mavorixafor
monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + meclofenamate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + meclofenamate
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + meclofenamate
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + mefenamic acid
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + mefenamic acid
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + mefenamic acid
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + meloxicam
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + meloxicam
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + meloxicam
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + mepivacaine
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + mepivacaine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + mepivacaine
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + meropenem
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism possibly induced)
Monitor/Modify Tx
indapamide + mesalamine
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + mesalamine
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
indapamide + mesalamine rectal
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + mesalamine rectal
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
indapamide + metformin
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + methamphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + methamphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + methamphetamine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + methazolamide
monitor sodium, potassium: combo may incr. risk of severe hyponatremia, hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + methohexital
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + methohexital
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + methohexital
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + methotrexate
monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)
telmisartan + methotrexate
monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (BCRP-mediated transport inhibited, additive effects)
Monitor/Modify Tx
amlodipine + methoxy polyethylene glycol-epoetin beta
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + methoxy polyethylene glycol-epoetin beta
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + methoxy polyethylene glycol-epoetin beta
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + methylene blue injection
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + methylene blue injection
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + methylene blue injection
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + methylergonovine
monitor BP: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)
indapamide + methylergonovine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + methylergonovine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + methylphenidate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + methylphenidate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + methylphenidate
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + methylprednisolone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + methylprednisolone
monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + methylprednisolone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + methyltestosterone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + methyltestosterone
monitor BP, calcium, especially if breast CA use: combo may incr. risk of hypercalcemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + methyltestosterone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + metoclopramide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + metoclopramide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + metoclopramide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + midazolam
monitor respiratory rate, BP: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + midazolam
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + midazolam
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + midodrine
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
indapamide + midodrine
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
telmisartan + midodrine
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
Monitor/Modify Tx
amlodipine + mifepristone
monitor BP during and x14 days after daily mifepristone use: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
indapamide + mifepristone
monitor potassium if daily mifepristone use: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
indapamide + miglitol
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + milnacipran
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + milnacipran
monitor BP, sodium: combo may incr. risk of severe hyponatremia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + milnacipran
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + milrinone
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + milrinone
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + milrinone
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + milsaperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + milsaperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + milsaperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + mirabegron
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + mirabegron
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + mirabegron
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + mirtazapine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + mirtazapine
monitor sodium, BP: combo may incr. risk of severe hyponatremia, hypotension, including orthostasis (additive effects)
telmisartan + mirtazapine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + mitapivat
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
indapamide + mitomycin
monitor renal fxn; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + mitomycin
monitor renal fxn; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + mitotane
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
telmisartan + mitoxantrone
monitor CBC, cardiac fxn, incl. LVEF: combo may incr. mitoxantrone levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (BCRP-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + mobocertinib
monitor ECG, BP: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + modafinil
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced, antagonistic effects)
indapamide + modafinil
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + modafinil
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + molindone
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + molindone
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + molindone
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + morphine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + morphine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + morphine
monitor respiratory rate, BP; consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), other adverse effects (P-gp-mediated transport inhibited, additive effects)
Monitor/Modify Tx
indapamide + motixafortide
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
telmisartan + mycophenolate mofetil
consider monitoring mycophenolic acid levels: combo may decr. mycophenolic acid levels, efficacy (UGT induced)
Monitor/Modify Tx
amlodipine + nabumetone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + nabumetone
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + nabumetone
monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + nafcillin
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + nalbuphine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + nalbuphine
monitor BP; consider incr. indapamide dose: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + nalbuphine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + naphazoline ophthalmic
consider monitoring BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + naphazoline ophthalmic
consider monitoring BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + naphazoline ophthalmic
consider monitoring BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + naproxen
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + naproxen
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + naproxen
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + naratriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + naratriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + naratriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + nateglinide
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
telmisartan + nateglinide
monitor glucose: combo may incr. risk of hypoglycemia (additive effects)
Monitor/Modify Tx
amlodipine + nattokinase
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + nattokinase
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + nattokinase
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + naxitamab
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
indapamide + naxitamab
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
telmisartan + naxitamab
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
Monitor/Modify Tx
indapamide + necitumumab
monitor potassium, magnesium: combo may incr. risk of hypokalemia, hypomagnesemia (additive effects)
Monitor/Modify Tx
amlodipine + nefazodone
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + nelfinavir
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + neomycin
if compromised gut wall allows for neomycin absorption, monitor renal fxn, ototoxicity: combo may incr. neomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
telmisartan + neomycin
if compromised gut wall allows for neomycin absorption, monitor renal fxn, ototoxicity: combo may incr. neomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + nevirapine
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + niacin (vitamin B3)
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + niacin (vitamin B3)
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + niacin (vitamin B3)
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
indapamide + nilotinib
monitor potassium, sodium: combo may incr. risk of hypokalemia, severe hyponatremia (additive effects)
telmisartan + nilotinib
monitor potassium: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
amlodipine + niraparib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + niraparib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + niraparib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + nitric oxide
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + nitric oxide
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + nitric oxide
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + nitrite
monitor BP: combo may incr. risk of severe or life-threatening hypotension, including syncope (additive effects)
indapamide + nitrite
monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)
telmisartan + nitrite
monitor BP: combo may incr. risk of severe or life-threatening hypotension, including syncope (additive effects)
Monitor/Modify Tx
amlodipine + nitroglycerin
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + nitroglycerin
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
telmisartan + nitroglycerin
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + nitroprusside
monitor BP: combo may incr. risk of severe or life-threatening hypotension (additive effects)
indapamide + nitroprusside
monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis (additive effects)
telmisartan + nitroprusside
monitor BP: combo may incr. risk of severe or life-threatening hypotension (additive effects)
Monitor/Modify Tx
amlodipine + nortriptyline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + nortriptyline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + nortriptyline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
indapamide + nusinersen
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + nusinersen
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + obinutuzumab
monitor BP: combo may incr. risk of hypotension; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
indapamide + obinutuzumab
monitor BP: combo may incr. risk of hypotension, including orthostasis; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + obinutuzumab
monitor BP: combo may incr. risk of hypotension; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + odevixibat
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + olanzapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + olanzapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + olanzapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + oliceridine
monitor respiratory rate, ECG, BP: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + oliceridine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + oliceridine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + olodaterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + olodaterol inhaled
monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + olodaterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + olsalazine
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + olsalazine
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + olutasidenib
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism possibly induced)
Monitor/Modify Tx
amlodipine + omaveloxolone
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
indapamide + omeprazole
monitor magnesium, especially w/ omeprazole tx >3mo: combo may incr. risk of hypomagnesemia, cardiac arrhythmias, tetany, seizures (additive effects)
Monitor/Modify Tx
amlodipine + opicapone
monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + opicapone
monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + opicapone
monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + opium
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + opium
monitor BP; consider incr. indapamide dose: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + opium
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + osilodrostat
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + osilodrostat
monitor BP, potassium: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + osilodrostat
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + oxaliplatin
monitor ECG, CBC, renal fxn, ototoxicity: combo may incr. oxaliplatin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
telmisartan + oxaliplatin
monitor ECG, CBC, renal fxn, ototoxicity: combo may incr. oxaliplatin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + oxaprozin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + oxaprozin
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + oxaprozin
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + oxazepam
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + oxazepam
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + oxazepam
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + oxcarbazepine
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
indapamide + oxcarbazepine
monitor sodium: combo may incr. risk of severe hyponatremia, seizures (additive effects)
telmisartan + oxcarbazepine
consider monitoring 10-hydroxyoxcarbazepine levels: combo may decr. oxcarbazepine active metabolite levels, efficacy (UGT induced)
Monitor/Modify Tx
amlodipine + oxymetazoline nasal
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + oxymetazoline nasal
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + oxymetazoline nasal
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + oxymetazoline ophthalmic
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + oxymetazoline ophthalmic
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + oxymetazoline ophthalmic
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + oxymetazoline topical
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + oxymetazoline topical
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + oxymetazoline topical
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + oxymorphone
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + oxymorphone
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + oxymorphone
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + oxytocin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + oxytocin
monitor sodium, BP: combo may incr. risk of severe hyponatremia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + oxytocin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + ozanimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ozanimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ozanimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + pacritinib
monitor ECG, CBC, BP, bleeding s/sx: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + paliperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + paliperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + paliperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + palopegteriparatide
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + palopegteriparatide
monitor BP, calcium: combo may incr. risk of hypercalcemia, hypotension, including orthostasis, syncope (additive effects)
telmisartan + palopegteriparatide
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
indapamide + pamidronate
monitor renal fxn, potassium, magnesium: combo may incr. pamidronate levels, risk of nephrotoxicity, hypokalemia, hypomagnesemia, other adverse effects (additive effects)
telmisartan + pamidronate
monitor renal fxn: combo may incr. pamidronate levels, risk of nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
indapamide + panitumumab
monitor potassium, magnesium: combo may incr. risk of hypokalemia, hypomagnesemia (additive effects)
Monitor/Modify Tx
indapamide + pantoprazole
monitor magnesium, especially w/ pantoprazole tx >3mo: combo may incr. risk of hypomagnesemia, cardiac arrhythmias, tetany, seizures (additive effects)
Monitor/Modify Tx
indapamide + paricalcitol
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
indapamide + paromomycin
if compromised gut wall allows for paromomycin absorption, monitor renal fxn, ototoxicity: combo may incr. paromomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
telmisartan + paromomycin
if compromised gut wall allows for paromomycin absorption, monitor renal fxn, ototoxicity: combo may incr. paromomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
indapamide + paroxetine
monitor sodium: combo may incr. risk of severe hyponatremia (additive effects)
Monitor/Modify Tx
indapamide + patiromer
monitor magnesium: combo may incr. risk of hypomagnesemia (additive effects)
telmisartan + patiromer
separate admin. by at least 3h: combo may decr. telmisartan levels, efficacy (absorption decreased)
Monitor/Modify Tx
indapamide + pegloticase
monitor uric acid levels: combo may decr. pegloticase efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + pemetrexed
monitor CBC, renal fxn: combo may incr. pemetrexed levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
telmisartan + pemetrexed
monitor CBC, renal fxn: combo may incr. pemetrexed levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + pemigatinib
monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + penicillamine
monitor CBC, renal fxn: combo may incr. penicillamine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
telmisartan + penicillamine
monitor CBC, renal fxn: combo may incr. penicillamine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + pentamidine
monitor BP: combo may incr. risk of severe or life-threatening hypotension (additive effects)
indapamide + pentamidine
monitor renal fxn, BP: combo may incr. risk of nephrotoxicity, severe or life-threatening hypotension, including orthostasis (additive effects)
telmisartan + pentamidine
monitor renal fxn, BP: combo may incr. risk of nephrotoxicity, severe or life-threatening hypotension (additive effects)
Monitor/Modify Tx
amlodipine + pentazocine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + pentazocine
monitor BP; consider incr. indapamide dose: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + pentazocine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + pentobarbital
monitor BP: combo may decr. (lev)amlodipine levels, efficacy; may incr. risk of hypotension (hepatic metabolism induced; additive effects)
indapamide + pentobarbital
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + pentobarbital
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + pentostatin
monitor CBC, renal fxn: combo may incr. pentostatin levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)
telmisartan + pentostatin
monitor CBC, renal fxn: combo may incr. pentostatin levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + pentoxifylline
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + pentoxifylline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + pentoxifylline
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + perampanel
monitor BP if on perampanel 12 mg/day: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + perphenazine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + perphenazine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
telmisartan + perphenazine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + pexidartinib
monitor BP: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced, antagonistic effects)
indapamide + pexidartinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + pexidartinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + phendimetrazine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + phendimetrazine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + phendimetrazine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + phenelzine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + phenelzine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + phenelzine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + phenobarbital
monitor BP: combo may decr. (lev)amlodipine levels, efficacy; may incr. risk of hypotension, including orthostasis (hepatic metabolism induced; additive effects)
indapamide + phenobarbital
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + phenobarbital
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + phentermine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + phentermine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + phentermine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + phenylephrine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + phenylephrine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + phenylephrine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + phenylephrine injection
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
indapamide + phenylephrine injection
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
telmisartan + phenylephrine injection
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
Monitor/Modify Tx
amlodipine + phenylephrine nasal
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + phenylephrine nasal
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + phenylephrine nasal
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + phenylephrine ophthalmic
monitor BP; HTN risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + phenylephrine ophthalmic
monitor BP; HTN risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + phenylephrine ophthalmic
monitor BP; HTN risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + phenylephrine rectal
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + phenylephrine rectal
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + phenylephrine rectal
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + phenytoin
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + pioglitazone
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
indapamide + pioglitazone
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + piroxicam
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + piroxicam
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + piroxicam
monitor BP, renal fxn, potassium: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
telmisartan + pitavastatin
monitor CK, myopathy sx: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited)
Monitor/Modify Tx
indapamide + plazomicin
monitor plazomicin levels, renal fxn, ototoxicity: combo may incr. plazomicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
telmisartan + plazomicin
monitor plazomicin levels, renal fxn, ototoxicity: combo may incr. plazomicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
indapamide + polyethylene glycol
monitor renal fxn, sodium, potassium, consider monitoring ECG if polyethylene glycol bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, severe hyponatremia, seizures, renal impairment (additive effects)
telmisartan + polyethylene glycol
monitor renal fxn, especially if polyethylene glycol bowel prep use: combo may incr. risk of renal impairment (additive effects)
Monitor/Modify Tx
indapamide + polyethylene glycol/ electrolytes
monitor renal fxn, sodium, potassium, consider monitoring ECG: combo may incr. risk of renal impairment, severe hyponatremia, seizures, hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)
telmisartan + polyethylene glycol/ electrolytes
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Monitor/Modify Tx
indapamide + polymyxin B
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + polymyxin B
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + ponatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ponatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ponatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + ponesimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ponesimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ponesimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + posaconazole
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
indapamide + posaconazole
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
telmisartan + potassium acid phosphate
monitor potassium: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
telmisartan + potassium bicarbonate
monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)
Monitor/Modify Tx
telmisartan + potassium citrate
monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)
Monitor/Modify Tx
telmisartan + potassium iodide
monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)
Monitor/Modify Tx
amlodipine + pramipexole
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + pramipexole
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + pramipexole
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
indapamide + pramlintide
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
telmisartan + pravastatin
monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + prazosin
monitor BP, especially during prazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + prazosin
monitor BP, especially during prazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + prazosin
monitor BP, especially during prazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + prednisolone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + prednisolone
monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + prednisolone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + prednisone
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced, antagonistic effects)
indapamide + prednisone
monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + prednisone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + primidone
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
indapamide + primidone
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
indapamide + probenecid
monitor uric acid levels: combo may decr. probenecid efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + procarbazine
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + procarbazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + procarbazine
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + prochlorperazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + prochlorperazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + prochlorperazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + promethazine
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + promethazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + promethazine
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + propofol
monitor BP: combo may incr. risk of severe hypotension (additive effects)
indapamide + propofol
monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
telmisartan + propofol
monitor BP: combo may incr. risk of severe hypotension (additive effects)
Monitor/Modify Tx
amlodipine + protriptyline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + protriptyline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + protriptyline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + pseudoephedrine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + pseudoephedrine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + pseudoephedrine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + quetiapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antihypertensive agent efficacy (peds patients) (additive effects, antagonistic effects)
indapamide + quetiapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antihypertensive agent efficacy (peds patients) (additive effects, antagonistic effects)
telmisartan + quetiapine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antihypertensive agent efficacy (peds patients) (additive effects, antagonistic effects)
Monitor/Modify Tx
amlodipine + quinidine (antiarrhythmic)
monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
indapamide + quinidine (antiarrhythmic)
monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal excretion possibly decreased at higher urine pH)
telmisartan + quinidine (antiarrhythmic)
monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
indapamide + quinidine (CYP2D6 inhibitor)
monitor ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (renal excretion possibly decreased at higher urine pH)
Monitor/Modify Tx
indapamide + rabeprazole
monitor magnesium, especially w/ rabeprazole tx >3mo: combo may incr. risk of hypomagnesemia, cardiac arrhythmias, tetany, seizures (additive effects)
Monitor/Modify Tx
amlodipine + ramucirumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ramucirumab
monitor sodium, BP: combo may incr. risk of severe hyponatremia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + ramucirumab
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
telmisartan + ranolazine
monitor ECG: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + rasagiline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + rasagiline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + rasagiline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
indapamide + rasburicase
monitor uric acid levels: combo may decr. rasburicase efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + red yeast rice
monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, red yeast rice contains varying amounts of lovastatin)
Monitor/Modify Tx
amlodipine + regorafenib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + regorafenib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + regorafenib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + remifentanil
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + remifentanil
monitor BP; consider incr. indapamide dose: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + remifentanil
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + remimazolam
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + remimazolam
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + remimazolam
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + repaglinide
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
telmisartan + repaglinide
monitor glucose: combo may incr. risk of hypoglycemia (additive effects)
Monitor/Modify Tx
indapamide + Rho(D) immune globulin
monitor renal fxn; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + Rho(D) immune globulin
monitor renal fxn; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + ribociclib
monitor BP, ECG, electrolytes, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypotension, edema, myelosuppression, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + rifabutin
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + rifampin
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + rifapentine
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + rimegepant
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + rimegepant
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + rimegepant
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + riociguat
monitor BP: combo may incr. risk of severe hypotension (additive effects)
indapamide + riociguat
monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
telmisartan + riociguat
consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (BCRP-mediated transport inhibited, additive effects)
Monitor/Modify Tx
amlodipine + ripretinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ripretinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ripretinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + risperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + risperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + risperidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + ritonavir
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + rituximab
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + rituximab
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + rizatriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + rizatriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + rizatriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + romidepsin
monitor sodium, magnesium: combo may incr. risk of severe hyponatremia, hypomagnesemia (additive effects)
Monitor/Modify Tx
indapamide + ropeginterferon alfa-2b
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + ropeginterferon alfa-2b
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + ropinirole
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
indapamide + ropinirole
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
telmisartan + ropinirole
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
Monitor/Modify Tx
amlodipine + ropivacaine
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + ropivacaine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + ropivacaine
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + rosiglitazone
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
telmisartan + rosuvastatin
monitor CK, myopathy sx: combo may incr. rosuvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + rotigotine transdermal
monitor BP: combo may alter blood pressure control (antagonistic effects, additive effects)
indapamide + rotigotine transdermal
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
telmisartan + rotigotine transdermal
monitor BP: combo may alter blood pressure control (antagonistic effects, additive effects)
Monitor/Modify Tx
amlodipine + rufinamide
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
indapamide + sacituzumab govitecan
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + sacubitril
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + sacubitril
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + sacubitril
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + safinamide
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + safinamide
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + safinamide
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + salmeterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + salmeterol inhaled
monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + salmeterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + salsalate
monitor BP w/ high-dose salsalate: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + salsalate
monitor renal fxn, BP w/ high-dose salsalate: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + salsalate
monitor renal fxn, BP w/ high-dose salsalate: combo may incr. risk of renal impairment; may decr. antihypertensive efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + sarilumab
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)
Monitor/Modify Tx
indapamide + saxagliptin
monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + selegiline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + selegiline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + selegiline
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + selegiline transdermal
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + selegiline transdermal
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + selegiline transdermal
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
indapamide + selinexor
monitor sodium, potassium: combo may incr. risk of severe hyponatremia (including life-threatening), hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + selpercatinib
monitor BP, ECG, electrolytes: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)
indapamide + selpercatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + selpercatinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + semaglutide
monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + sertraline
monitor sodium: combo may incr. risk of severe hyponatremia (additive effects)
Monitor/Modify Tx
amlodipine + sevoflurane
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + sevoflurane
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + sevoflurane
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + sildenafil
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + sildenafil
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + sildenafil
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + silodosin
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + silodosin
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + silodosin
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + sincalide
if sincalide gallbladder contraction stimulation use, consider D/C amlodipine prior to sincalide admin.: combo may alter sincalide efficacy, interfere with test results (gallbladder motility/contractility altered)
Monitor/Modify Tx
amlodipine + siponimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + siponimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + siponimod
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + sirolimus
monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited)
indapamide + sirolimus
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + sirolimus
monitor sirolimus levels, renal fxn: combo may incr. sirolimus levels, risk of serious infection, nephrotoxicity, other adverse effects (P-gp-mediated transport inhibited, additive effects)
Monitor/Modify Tx
indapamide + sitagliptin
monitor glucose, renal fxn: combo may incr. risk of nephrotoxicity; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)
telmisartan + sitagliptin
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
indapamide + sodium benzoate
monitor potassium, especially if hyperammonemia use: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + sodium ferric gluconate complex
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + sodium ferric gluconate complex
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + sodium ferric gluconate complex
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + sodium phenylacetate
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
indapamide + sodium phenylbutyrate
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + sodium polystyrene sulfonate
separate admin. by at least 3h (6h if gastroparesis); rectal sodium polystyrene sulfonate use OK: combo may decr. (lev)amlodipine levels, efficacy (absorption decreased)
indapamide + sodium polystyrene sulfonate
monitor magnesium, potassium, ECG: combo may incr. risk of hypomagnesemia, hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)
Monitor/Modify Tx
indapamide + sodium thiosulfate
if ototoxicity risk reduction use, monitor potassium; otherwise, caution advised: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + sorafenib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + sorafenib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + sorafenib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + sotagliflozin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + sotagliflozin
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + sotagliflozin
monitor BP: combo may decr. sotagliflozin levels, efficacy; may incr. risk of hypotension, including orthostasis (UGT induced; additive effects)
Monitor/Modify Tx
amlodipine + sotalol
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + sotalol
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + sotalol
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + sotorasib
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
indapamide + spironolactone
monitor renal fxn, electrolytes: combo may incr. risk of renal impairment, severe hyponatremia, hypomagnesemia, other adverse effects (additive effects, duplicate therapy)
telmisartan + spironolactone
monitor potassium, renal fxn: combo may incr. risk of severe hyperkalemia, renal impairment (additive effects)
Monitor/Modify Tx
amlodipine + St. John's wort
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + stiripentol
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism possibly induced)
Monitor/Modify Tx
indapamide + streptomycin
monitor renal fxn, ototoxicity: combo may incr. streptomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
telmisartan + streptomycin
monitor renal fxn, ototoxicity: combo may incr. streptomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
indapamide + streptozocin
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + streptozocin
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
telmisartan + succinylcholine
monitor potassium: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
amlodipine + sufentanil
monitor respiratory rate, BP; consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + sufentanil
monitor BP; consider incr. indapamide dose: combo may incr. risk of severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + sufentanil
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
indapamide + sulfate bowel prep
monitor renal fxn, sodium, potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, renal impairment, severe hyponatremia, seizures (additive effects)
telmisartan + sulfate bowel prep
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Monitor/Modify Tx
amlodipine + sulindac
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + sulindac
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + sulindac
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + sumatriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + sumatriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + sumatriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + sunitinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + sunitinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + sunitinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + sunvozertinib
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + suzetrigine
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + tadalafil
monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + tadalafil
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + tadalafil
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + tafasitamab
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
amlodipine + tagraxofusp
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
indapamide + tagraxofusp
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
telmisartan + tagraxofusp
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
Monitor/Modify Tx
telmisartan + talazoparib
monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)
Monitor/Modify Tx
amlodipine + taletrectinib
monitor ECG: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + tamsulosin
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + tamsulosin
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + tamsulosin
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + tapentadol
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + tapentadol
monitor BP; consider indapamide dose adjustment: combo may increase risk of severe hypotension, including orthostasis, syncope; may decrease indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + tapentadol
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + taurine
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + taurine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + taurine
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + tazemetostat
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + tecovirimat
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
indapamide + telavancin
monitor ECG, renal fxn: combo may incr. telavancin levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (additive effects)
telmisartan + telavancin
monitor ECG, renal fxn: combo may incr. telavancin levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + telotristat ethyl
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + temsirolimus
monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, angioedema, other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + temsirolimus
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + temsirolimus
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
indapamide + tenofovir alafenamide
monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)
telmisartan + tenofovir alafenamide
monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut BCRP-mediated transport inhibited, gut P-gp-mediated transport inhibited, additive effects)
Monitor/Modify Tx
indapamide + tenofovir disoproxil
monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)
telmisartan + tenofovir disoproxil
monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited, additive effects)
Monitor/Modify Tx
amlodipine + terazosin
monitor BP, especially during terazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + terazosin
monitor BP, especially during terazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + terazosin
monitor BP, especially during terazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + terbutaline
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + terbutaline
monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + terbutaline
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + teriflunomide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + teriflunomide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + teriflunomide
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + teriparatide
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
amlodipine + testosterone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + testosterone
monitor BP, calcium, especially in cancer pts at incr. risk: combo may incr. risk of hypercalcemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + testosterone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + tetrahydrozoline ophthalmic
consider monitoring BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + tetrahydrozoline ophthalmic
consider monitoring BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + tetrahydrozoline ophthalmic
consider monitoring BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + thalidomide
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + thalidomide
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + thalidomide
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + thioridazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + thioridazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + thioridazine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + thiothixene
monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)
indapamide + thiothixene
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + thiothixene
monitor BP: combo may incr. risk of hypotension, including syncope (additive effects)
Monitor/Modify Tx
amlodipine + thyroid
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + thyroid
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + thyroid
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + timolol ophthalmic
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + timolol ophthalmic
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + timolol ophthalmic
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
indapamide + tiopronin
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + tiopronin
monitor renal fxn: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + tipranavir
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + tirzepatide
monitor glucose if type 2 diabetes mellitus use: combo may decr. antidiabetic agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + tivozanib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + tivozanib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + tivozanib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + tizanidine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + tizanidine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + tizanidine
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
indapamide + tobramycin
monitor tobramycin levels, renal fxn, electrolytes, ototoxicity: combo may incr. tobramycin levels, risk of nephrotoxicity, hypomagnesemia, auditory, vestibular, other adverse effects (additive effects)
telmisartan + tobramycin
monitor tobramycin levels, renal fxn, ototoxicity: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
indapamide + tobramycin inhaled
monitor renal fxn, ototoxicity: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
telmisartan + tobramycin inhaled
monitor renal fxn, ototoxicity: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + tocilizumab
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)
Monitor/Modify Tx
amlodipine + tolcapone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + tolcapone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + tolcapone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + tolmetin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + tolmetin
monitor renal fxn, BP: combo may incr. risk of renal impairment; may decr. indapamide efficacy (additive effects; antagonistic effects)
telmisartan + tolmetin
monitor renal fxn, potassium, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
amlodipine + tolvaptan
consider decr. tolvaptan dose: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metabolism inhibited)
telmisartan + tolvaptan
monitor potassium: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
amlodipine + topiramate
monitor BP, especially w/ topiramate doses >200 mg/day: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
indapamide + topiramate
monitor potassium: combo may incr. risk of hypokalemia (additive effects)
Monitor/Modify Tx
indapamide + toremifene
monitor calcium, especially if tumor flare risk: combo may incr. risk of hypercalcemia (possible additive effects)
Monitor/Modify Tx
indapamide + torsemide
monitor renal fxn, electrolytes: combo may incr. risk of renal impairment, severe hyponatremia, hypokalemia, hypomagnesemia, other adverse effects (additive effects, duplicate therapy)
telmisartan + torsemide
monitor renal fxn: combo may incr. risk of renal impairment (additive effects)
Monitor/Modify Tx
amlodipine + tovorafenib
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + tramadol
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
indapamide + tramadol
monitor sodium, BP: combo may incr. risk of severe hyponatremia, severe hypotension, including orthostasis, syncope; may decr. indapamide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release)
telmisartan + tramadol
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + trametinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + trametinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + trametinib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + tranylcypromine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + tranylcypromine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + tranylcypromine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + trazodone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + trazodone
monitor sodium, BP: combo may incr. risk of severe hyponatremia, hypotension, including orthostasis, syncope (additive effects)
telmisartan + trazodone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + treprostinil
monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)
indapamide + treprostinil
monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)
telmisartan + treprostinil
monitor BP: combo may incr. risk of severe hypotension, including syncope (additive effects)
Monitor/Modify Tx
amlodipine + triamcinolone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + triamcinolone
monitor potassium, BP: combo may incr. risk of hypokalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + triamcinolone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + triamterene
monitor sodium, renal fxn: combo may incr. risk of renal impairment, severe hyponatremia, other adverse effects (additive effects, duplicate therapy)
telmisartan + triamterene
monitor potassium: combo may incr. risk of severe hyperkalemia (additive effects)
Monitor/Modify Tx
amlodipine + triazolam
monitor respiratory rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + trifluoperazine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
indapamide + trifluoperazine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
telmisartan + trifluoperazine
monitor BP: combo may incr. risk of severe hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
telmisartan + trimethoprim
monitor potassium: combo may incr. risk of hyperkalemia (additive effects)
Monitor/Modify Tx
amlodipine + trimipramine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
indapamide + trimipramine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + trimipramine
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
Monitor/Modify Tx
amlodipine + tucatinib
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + ubrogepant
monitor BP; limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects; may decr. antihypertensive agent efficacy (hepatic metabolism inhibited; antagonistic effects)
indapamide + ubrogepant
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ubrogepant
monitor BP; limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects; may decr. antihypertensive agent efficacy (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited; antagonistic effects)
Monitor/Modify Tx
amlodipine + vaborbactam
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism possibly induced)
Monitor/Modify Tx
indapamide + vaccinia immune globulin
monitor renal fxn; use lowest vaccinia immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
telmisartan + vaccinia immune globulin
monitor renal fxn; use lowest vaccinia immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)
Monitor/Modify Tx
amlodipine + vadadustat
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + vadadustat
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + vadadustat
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + valacyclovir
monitor renal fxn: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)
telmisartan + valacyclovir
monitor renal fxn: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
indapamide + valganciclovir
monitor CBC, renal fxn: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
telmisartan + valganciclovir
monitor CBC, renal fxn: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
telmisartan + valproic acid
monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)
Monitor/Modify Tx
amlodipine + vamorolone
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism possibly induced, antagonistic effects)
indapamide + vamorolone
monitor BP, potassium: combo may decr. antihypertensive agent efficacy; may incr. risk of hypokalemia (antagonistic effects; additive effects)
telmisartan + vamorolone
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + vancomycin
VANCOMYCIN IV: monitor renal fxn, vancomycin levels, ototoxicity; VANCOMYCIN PO: consider monitoring renal fxn, vancomycin levels, ototoxicity in pts w/ severe renal impairment, severe intestinal inflammation, or prolonged course >2 g/day: combo may incr. vancomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects; incr. oral vancomycin absorption if inflamed or compromised gut mucosa)
telmisartan + vancomycin
VANCOMYCIN IV: monitor renal fxn, vancomycin levels, ototoxicity; VANCOMYCIN PO: consider monitoring renal fxn, vancomycin levels, ototoxicity in pts w/ severe renal impairment, severe intestinal inflammation, or prolonged course >2 g/day: combo may incr. vancomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects; incr. oral vancomycin absorption if inflamed or compromised gut mucosa)
Monitor/Modify Tx
amlodipine + vandetanib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + vandetanib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + vandetanib
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + vardenafil
monitor ECG, BP: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited, additive effects)
indapamide + vardenafil
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + vardenafil
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + vasopressin
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
indapamide + vasopressin
monitor BP, sodium: combo may incr. risk of severe hyponatremia; may decr. efficacy of both drugs (additive effects; antagonistic effects)
telmisartan + vasopressin
monitor BP: combo may decr. efficacy of both drugs (antagonistic effects)
Monitor/Modify Tx
amlodipine + vemurafenib
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + venlafaxine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + venlafaxine
monitor BP, sodium: combo may incr. risk of severe hyponatremia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + venlafaxine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + vilanterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + vilanterol inhaled
monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + vilanterol inhaled
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + vilazodone
monitor sodium: combo may incr. risk of severe hyponatremia (additive effects)
Monitor/Modify Tx
amlodipine + viloxazine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + viloxazine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + viloxazine
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + vinblastine
monitor CBC, BP: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + vincristine
monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
amlodipine + vinorelbine
monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + vitamin A (retinol)
monitor calcium: combo may incr. risk of hypercalcemia (additive effects)
Monitor/Modify Tx
amlodipine + voclosporin
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + voclosporin
monitor renal fxn, BP: combo may incr. risk of nephrotoxicity; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
telmisartan + voclosporin
monitor potassium, renal fxn, BP: combo may incr. risk of severe hyperkalemia, nephrotoxicity; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
indapamide + vonoprazan
monitor magnesium: combo may incr. risk of hypomagnesemia (additive effects)
Monitor/Modify Tx
amlodipine + vorasidenib
monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism possibly induced)
Monitor/Modify Tx
amlodipine + voriconazole
monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + vortioxetine
monitor sodium: combo may incr. risk of severe hyponatremia (additive effects)
Monitor/Modify Tx
amlodipine + vosoritide
monitor BP: combo may incr. risk of hypotension (additive effects)
indapamide + vosoritide
monitor BP: combo may incr. risk of hypotension, including orthostasis (additive effects)
telmisartan + vosoritide
monitor BP: combo may incr. risk of hypotension (additive effects)
Monitor/Modify Tx
amlodipine + warfarin
monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)
Monitor/Modify Tx
indapamide + willow bark
monitor renal fxn, especially w/ high-dose willow bark: combo may incr. risk of renal impairment (additive effects, willow bark may contain salicylates)
telmisartan + willow bark
monitor renal fxn, especially w/ high-dose willow bark: combo may incr. risk of renal impairment (additive effects, willow bark may contain salicylates)
Monitor/Modify Tx
amlodipine + yohimbe
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
indapamide + yohimbe
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
telmisartan + yohimbe
monitor BP: combo may alter blood pressure control (additive effects, antagonistic effects)
Monitor/Modify Tx
amlodipine + zanubrutinib
monitor CBC, BP: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. (lev)amlodipine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)
Monitor/Modify Tx
amlodipine + zavegepant
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + zavegepant
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + zavegepant
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
amlodipine + ziprasidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
indapamide + ziprasidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
telmisartan + ziprasidone
monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)
Monitor/Modify Tx
amlodipine + ziv-aflibercept
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + ziv-aflibercept
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + ziv-aflibercept
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + zoledronic acid
monitor renal fxn: combo may incr. zoledronic acid levels, risk of nephrotoxicity, other adverse effects (additive effects)
telmisartan + zoledronic acid
monitor renal fxn: combo may incr. zoledronic acid levels, risk of nephrotoxicity, other adverse effects (additive effects)
Monitor/Modify Tx
amlodipine + zolmitriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
indapamide + zolmitriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
telmisartan + zolmitriptan
monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)
Monitor/Modify Tx
indapamide + zonisamide
monitor potassium, renal fxn: combo may incr. risk of renal impairment, hypokalemia (additive effects)
Caution Advised
- acitretin
- artesunate
- cobimetinib
- conivaptan
- daridorexant
- elinzanetant
- glecaprevir
- icosapent ethyl
- methoxsalen
- mycophenolic acid
- naldemedine
- palovarotene
- pibrentasvir
- pimecrolimus topical
- rilzabrutinib
- roflumilast
- roflumilast topical
- seladelpar
- sirolimus topical
- sulfasalazine
- tacrolimus topical
- verteporfin
Caution Advised
indapamide + acitretin
caution advised: combo may incr. risk of photosensitivity reaction (additive effects)
Caution Advised
telmisartan + artesunate
caution advised: combo may decr. dihydroartemisinin levels, efficacy (UGT induced; artesunate converted to dihydroartemisinin by esterases)
Caution Advised
amlodipine + cobimetinib
caution advised: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)
Caution Advised
amlodipine + conivaptan
caution advised: combo may incr. conivaptan levels, risk of overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metabolism inhibited)
Caution Advised
amlodipine + daridorexant
caution advised: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)
Caution Advised
amlodipine + elinzanetant
caution advised: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)
Caution Advised
telmisartan + glecaprevir
caution advised: combo may incr. glecaprevir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)
Caution Advised
indapamide + icosapent ethyl
caution advised: combo may antagonize antihyperlipidemic effect of omega-3-acid (antagonistic effects)
Caution Advised
indapamide + methoxsalen
caution advised: combo may incr. risk of photosensitivity reaction (additive effects)
Caution Advised
telmisartan + mycophenolic acid
caution advised: combo may decr. mycophenolic acid levels, efficacy (UGT induced)
Caution Advised
telmisartan + naldemedine
caution advised: combo may incr. naldemedine levels, risk of adverse effects (P-gp-mediated transport inhibited)
Caution Advised
amlodipine + palovarotene
caution advised: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)
Caution Advised
telmisartan + pibrentasvir
caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)
Caution Advised
amlodipine + pimecrolimus topical
caution advised: combo may incr. pimecrolimus levels, risk of serious infection, other adverse effects (hepatic metabolism possibly inhibited)
Caution Advised
amlodipine + rilzabrutinib
caution advised: combo may incr. rilzabrutinib levels, risk of adverse effects (hepatic metabolism inhibited)
Caution Advised
amlodipine + roflumilast
caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)
Caution Advised
amlodipine + roflumilast topical
caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)
Caution Advised
telmisartan + seladelpar
caution advised if also combined with OATP1B1 and/or OATP1B3 inhibitor: combo may incr. seladelpar levels, risk of adverse effects (BCRP-mediated transport inhibited)
Caution Advised
amlodipine + sirolimus topical
caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metabolism inhibited)
Caution Advised
telmisartan + sulfasalazine
caution advised: combo may incr. sulfasalazine levels, risk of adverse effects; may decr. IBD tx efficacy (gut BCRP-mediated transport inhibited)
Caution Advised
amlodipine + tacrolimus topical
caution advised: combo may incr. tacrolimus levels, risk of adverse effects (hepatic metabolism inhibited)
Caution Advised
amlodipine + verteporfin
caution advised: combo may enhance rate of verteporfin uptake into vascular endothelium (mechanism unknown)
indapamide + verteporfin
caution advised: combo may incr. risk of photosensitivity reaction (additive effects)
Adverse Reactions .
Serious Reactions
-
com.epocrates.rxweb.beans.StringCollection@2bfb60fb
- hypersensitivity reaction
- anaphylaxis
- angioedema
- erythema multiforme
- hypotension, severe
- angina exacerbation
- MI
- hyperkalemia
- hypokalemia
- electrolyte imbalance
- renal impairment
- renal failure
- anemia
- thrombocytopenia
- hepatitis
- cholestatic jaundice
- rhabdomyolysis
- SLE exacerbation
- glaucoma, acute angle-closure
- acute myopia
- choroidal effusion
- photosensitivity
Common Reactions
-
com.epocrates.rxweb.beans.StringCollection@1da73b14
- hypotension
- hyponatremia
- hypokalemia
- hyperuricemia
- hyperglycemia
- headache
- peripheral edema
Safety/Monitoring .
Monitoring Parameters
BUN/Cr at baseline, then periodically; electrolytes; glucose; uric acid; HR
Pregnancy/Lactation .
Pregnancy
Clinical Summary
telmisartan: avoid use during pregnancy; if must use, monitor amniotic fluid and fetus closely; risk of fetal and neonatal harm, including intrauterine growth restriction, oligohydramnios, renal failure, and death, in 2nd and 3rd trimesters based on human data and drug's mechanism of action
amlodipine: weigh risk/benefit during pregnancy; inadequate human data available; no known risk of teratogenicity, though risk of embryo-fetal death based on animal data at 10x and 20x MRHD
indapamide: may use during pregnancy if on chronic tx before conception, otherwise weigh risk/benefit; no known risk of teratogenicity based on human data; possible risk of decr. placental perfusion and neonatal adverse effects, including hypoglycemia, thrombocytopenia, and electrolyte abnormalities, based on limited or conflicting human data; risks not observed if chronic use before conception
Lactation
Clinical Summary
telmisartan: weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
amlodipine: weigh risk/benefit while breastfeeding; no known risk of infant harm based on limited human data; no human data available to assess effects on milk production
indapamide: weigh risk/benefit while breastfeeding; no human data available, though no known risk of infant harm based on limited human data with other thiazide diuretics; possible decr. milk production based on limited human data with other high-dose thiazide diuretics
Pharmacology .
com.epocrates.rxweb.beans.DrugOtherInfoBean@6b15ade9Metabolism: for telmisartan: liver minimally; CYP450: none; for amlodipine: liver extensively; CYP450: 3A4 substrate; for indapamide: liver extensively; CYP450: unknown
Excretion: for telmisartan: bile/feces >97% (100% unchanged), urine <1%; Half-life: 24h; for amlodipine: urine 59-62% (5-10% unchanged), bile/feces 20-25%; Half-life: 30-50h, 56h (hepatic impairment); for indapamide: urine 70% (5-7% unchanged), GI tract 23%; Half-life: 26h
Subclass: Angiotensin Receptor Blockers (ARBs) ; Calcium Channel Blockers (CCBs), Dihydropyridines ; Diuretics, Thiazides
Mechanism of Action
for telmisartan: selectively antagonizes angiotensin II AT1 receptors; for amlodipine: inhibits calcium ion influx into vascular smooth muscle and myocardium; for indapamide: inhibits distal convoluted tubule sodium and chloride reabsorption
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.